

International Society for Heart and Lung Transplantation

21st Annual Meeting and Scientific Sessions

Final Program

April 25-28, 2001

Convening at the Vancouver Convention and Exhibition Centre, Vancouver, Canada

## **International Society for Heart and Lung Transplantation**

### President

Anne Keogh, MBBS, MD, Sydney, Australia

### President-Elect

James B. Young, MD, Cleveland, OH

### Past President

Robert L. Kormos, MD, Pittsburgh, PA

### Secretary/Treasurer

Alec Patterson, MD, St. Louis, MO

### Directors

Linda J. Addonizio, MD, New York, NY

Marshall Hertz, MD, Minneapolis, MN

Stephan Schueler, MD, Dresden, Germany

Susan Stewart, FRCPath, Cambridge, United Kingdom

Robert C. Bourge, MD, Birmingham, AL

Axel Haverich, MD, Hannover, Germany

Mehmet C. Oz, MD, New York, NY

Sabina M. De Geest, RN, PhD, Basel, Switzerland

W. Steves Ring, MD, Dallas, TX

Robert C. Robbins, MD, Stanford, CA

David O. Taylor, MD, Salt Lake City, UT

### JHLT Editor

James K. Kirklin, MD, Birmingham, AL

### Registry Medical Director

Jeffrey D. Hosenpud, MD, Milwaukee, WI

### Staff

Amanda W. Rowe

Executive Director

Phyllis Glenn

Assistant Executive Director

Director of Membership Services

Lisa Ramirez

Director of Meetings

Leslie Heredia

Administrative Assistant

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

[www.ishlt.org](http://www.ishlt.org)

# INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION

## PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD

## **INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION**

### **AWARD RECIPIENTS**

#### **LIFETIME SERVICE AWARD**

1996 Michael Kaye  
1997 Jaques Losman

#### **LIFETIME ACHIEVEMENT AWARD**

1999 Keith Reemtsma, MD  
1998 Norman Shumway, MD

#### **ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD**

2000 Gordon D. Wu, MD

#### **ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1998 Scott D. Ross, MD

#### **ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1997 Owen T. Lawrence, MD  
1996 Andrew F. Pierre, MD  
1995 Frances L. Johnson, MD

#### **ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT**

2000 Christopher H. Wigfield, FRCS  
1999 Donald Wong, PhD  
Sivasai Krovvidi, PhD  
1998 Kelly S.A. Blair, MD  
A.M. El Gamel, MD  
1997 Jonathen Chen, MD  
Anne K. Raisanen-Sokolowski, MD  
1996 Tuija S. Ikonen, MD

#### **ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT**

2000 Richard S. Lee, MD  
1999 George Juang, MD  
Satoshi Saito, MD  
1998 Margaret L. Schwarze, MD

#### **ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1998 Christine L. Lau, MD

#### **ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT**

1999 Alyssa M. Krasinskas, MD

#### **ISHLT NURSING RESEARCH GRANT**

2000 Nancy M. Albert, MSN, RN  
1999 Jeanne Salyer, PhD  
1998 Katherine St. Clair, RN, MSN  
1997 Eileen Collins, RN, PhD

#### **CAVES AWARD**

2000 Michael P. Fischbein, MD  
1999 Joerg Koglin, MD  
1998 Carla C. Baan, MD  
1997 Simon D. Eiref, MD  
1996 Moninder S. Bhabra, MD

1995 Elizabeth A. Davis, MD  
1994 Jobst Winter, MD  
1994 Alain Chapelier, MD  
1993 David Marshman, MD  
1992 David P. Kapelanski, MD  
1991 A. Jiminez, MD  
1990 Andres J. Duncan, MD  
1989 A.M. Wood, MD  
1988 Charles D. Fraser, Jr., MD  
1987 Wim Van Der Bij, MD  
1986 Stuart J. Knechtle, MD  
1985 Michael A. Breda, MD  
1984 Hermann Reichensperner, MD  
1983 Robbin G. Cohen, MD

## HIGHLIGHTS OF THE SCIENTIFIC PROGRAM

Don't miss the following at this year's meeting:

**Invited Lecture Series:** Each Plenary Session will feature lectures from international experts. Come and learn what's new with The Human Genome Project, cell transplantation, the artificial lung, pediatric immunosuppression, and the role of the endothelium in rejection.

**Late Breaking Clinical Trials:** This highly rated abstract features the latest study on the Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients with Pulmonary Hypertension: A Placebo-Control Study.

**Provocative Debates:** Closing the meeting with an energetic debate on an issue of polarized opinion has become one of the hallmarks of the ISHLT meeting. Join us for this year's debates: A "Marginal Heart" Transplant is Better than a VAD Bridge, and Lung Allocation: Medical Urgency, Not Time on List.

**Case Reports:** Learn from the experience of others during Friday's Sunrise Symposia: Current Issues Allograft Vasculopathy, Would You Use This Lung Donor?, More VADs Gone Bad, and Anything But a Biopsy: Noninvasive Rejection Detection and Saturday's Sunrise Symposia: Fantastic Failures and Sensational Successes in Heart, Lung and Pediatric Transplantation.

**Basics of Transplantation:** To encourage participation in this meeting among those who are new to transplantation, those in training, and those who are in need of a refresher course, we are offering an educational track in the basics of transplantation. This will begin with a Satellite Symposium on Wednesday reviewing the basics of transplantation immunology. We will be offering two Mid-Day workshops, entitled "Core Curriculum Courses" one addressing thoracic transplant pathology and one delving into new insights into the pharmacology of immunosuppressive agents.

## **CONTINUING MEDICAL EDUCATION INFORMATION**

### **Accreditation**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 31 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Category I Continuing Education Points for Transplant Coordinators (CEPTs) have been applied for through the American Board of Transplant Coordinators (ABTC).

This program has been submitted to the American Association of Critical Care Nurses (AACN) Certification Corporation for continuing education credit approval.

This program has been submitted to the Association of Social Work Boards for continuing education credit approval.

### **Disclosure**

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown on page \_\_\_ of this program. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

## **Educational Objectives**

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

## **Goals**

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

## **Target Audience**

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

## **Learning Objectives**

At the conclusion of this meeting, participants should be able to:

- \* identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
- \* compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- \* understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- \* compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- \* describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
- \* understand current animal models of basic science immunology and their application to the transplant setting
- \* evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
- \* understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
- \* identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
- \* evaluate the current and developing alternatives to orthotopic transplantation, including mechanical circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
- \* evaluate and implement the use of alternative methods of monitoring and treating rejection
- \* identify, prevent, and treat donor-transmitted diseases



Faculty Name & Presentation	Company Affiliation	Relationship
Marshall Hertz, MD Satellite Symposium 1	Novartis, Wyeth-Ayerst	Research Support
Jack Copeland, MD Satellite Symposium 2	CardioWest	Medical Advisor
Mehmet Oz, MD Satellite Symposium 2	TCI, Thoratec, Abiomed	Speaker Bureau
Walter E. Pae, Jr., MD Satellite Symposium 2	Arrow International	Research Support
Peer M. Portner, MD Satellite Symposium 2	World Heart Corporation	Consultant
Richard Channick, MD Satellite Symposium 3 and (Abstract #331)	Actelion and INO Therapeutics	Research Support
Robyn Barst, MD Satellite Symposium 3	United Therapeutics	Consultant and Member SAB
David Farrar, MD Satellite Symposium 3	Thoratec	Employee
Paul A. Corris, MD (Abstract #3) Funding	Roche and Novartis	Scientific Advising Committee Member and Research
Galen M. Peiper, MD (Abstract #24)	AnorMED, Inc.	Company Grant-In-Aid
Joren Madsen, MD, Dphil (Abstract #34)	Roche	Supplied MMF and Research Funding
Randall Yatscoff, MD (Abstract #36)	Isotechnika, Inc.	President & COO
Jeffrey Hosenpud, MD (Abstract #38)	Novartis	Travel Support
Allan R. Glanville, MD, FRACP (Abstract #66)	Aventis Pharma	Research Support
Andreas Zuckermann, MD Sunrise Symposium 1	Sangstat	Speaker
Hani N. Sabbah, MD (Abstract #119 and #198)	Acorn Cardiovascular	Research Grant and Consultant
Andreas Zuckerman, MD (Abstract #140)	Sangstat	Scientific Support
Martin Zamora, MD (Abstract # 151)	Medimmune	Consultant, Lecturer and Research Support
Maria Frigerio, MD (Abstract #197)	Medtronic	Support for Anonymous Data Analysis
Hermann Reichensperner, MD (Abstract #199)	Myocor, Inc.	Scientific Advisor
Robert Scott, MD (Abstract #297)	Astra Zeneca	Speakers Bureau
Xinfan Huang, MD		

(Abstract #302)	Connectics Corp.	Employee
Clare R. Gregory, DVM (Abstract #303)	Novartis AG	Research Support
Sandra V. Chaparro, MD (Abstract #318)	Roche	Research Support
Mark M. Boucek, MD (Abstract #327)	Sangstat	Research Support and Consultant
Bruno Meiser, MD Mid-Day Workshop 2	Fujisawa GmbH	Consultant

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of our corporate partners towards this Twenty-First Annual Meeting and Scientific Sessions

PLATINUM PARTNER

Novartis  
Roche

GOLD PARTNER

Fujisawa Healthcare USA

SILVER PARTNER

SangStat Medical Corporation

BRONZE PARTNER

Actelion Pharmaceuticals, Inc.  
MedImmune  
Schering AG  
Thoratec Corporation

toward this

TWENTY FIRST ANNUAL MEETING AND SCIENTIFIC SESSIONS

## SCIENTIFIC PROGRAM

NOTE: All meetings and activities will take place at the Vancouver Convention and Exhibition Centre unless otherwise specified. All papers will be presented in English.

Wednesday, April 25, 2001

7:00 am-9:00 am

ISHLT Editorial Board Meeting (Governor General Suite C/D, Pan Pacific Hotel)

7:00 am-9:00 am

ISHLT Registry Committee Meeting (Gazebo I, Pan Pacific Hotel)

8:00 am-2:00 pm

ISHLT Board of Directors Meeting (Canada Suite, Pan Pacific Hotel)

10:00 am-6:00 pm

Registration (Convention Centre Lobby)

8:00 am-5:00 pm

Exhibitor Set Up (Exhibit Hall C)

Noon-5:00 pm

Poster Display Session 1 Set-Up (Exhibit Hall C)

12:30 pm-3:00 pm

**Satellite Symposium 1: BOS: Natural History, Diagnosis, Grading, and Therapy** (Ballroom A)

Co-Chairs: Elbert P. Trulock, MD and Allan R. Glanville, MD

12:30 pm **History and Impact**, Allan R. Glanville, MD, FRACP, St. Vincent's Hospital, Sydney, Australia

12:45 pm **Risk Factors**, Linda Sharples, PhD, Papworth Hospital NHS Trust, Cambridge, United Kingdom

1:05 pm **Pathology**, Susan Stewart, FRCPath, Papworth Hospital NHS Trust, Cambridge, United Kingdom

1:20 pm **Physiology**, Marc Estenne, MD, Erasme Hospital, Brussels, Belgium

1:50 pm **Diagnostic Criteria Review**, Janet R. Maurer, MD, Cleveland Clinic Foundation, Cleveland, OH

2:20 pm **Therapy – State of the Art**, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

12:30 pm-3:00 pm

**Satellite Symposium 2: Ventricular Assist Therapy Update: The \$6 Million (Hu)Man Revisited** (Ballroom B)

Co-Chairs: Patrick M. McCarthy, MD and William S. Pierce, MD

12:30 pm **Novacor/Worldheart**, Peer M. Portner, PhD, Stanford University School of Medicine, Palo Alto, CA

12:45 pm **TCI and Rematch**, Eric A. Rose, MD, Columbia Presbyterian Medical Center, New York, NY

1:00 pm **Thoratec**, David J. Farrar, PhD, California Pacific Medical Center, San Francisco, CA

1:15 pm **CardioWest**, Jack G. Copeland, MD, University of Arizona Health Science Center, Tucson, AZ

1:30 pm **Arrow LionHeart**, Walter E. Pae, Jr., MD, Milton S. Hershey Medical Center, Hershey, PA

1:45 pm **MicroMed DeBakey**, George P. Noon, MD, Baylor College of Medicine, Houston, TX

2:00 pm **Jarvik 2000**, O. Howard Frazier, MD, Texas Heart Institute, Houston, TX

2:15 pm **CardioVAD**, Valluvan Jeevanandam, MD, University of Chicago, Chicago, IL

2:30 pm **Debate: Controversies on Weaning from VAD Support, The Berlin Experience**, Johannes Mueller, MD, German Heart Institute

2:45 pm **Debate: Controversies on Weaning from VAD Support, The Columbia Experience**, Mehmet C. Oz, MD, Columbia Presbyterian Medical Center, New York, NY

3:00 pm-3:30 pm Coffee Break (Delegate Concourse)

3:30 pm-6:00 pm

**Satellite Symposium 3: Pulmonary Hypertension: Just Say Yes to Drugs** (Ballroom A)

Co-Chairs: Keith McNeil, FRACP and Anne Keogh, MBBS, MD

3:30 pm **TGF $\beta$  Receptors and Pulmonary Hypertension**, Richard C. Trembath, MB, FRCP, University of Leicester, Leicester, United Kingdom

3:50 pm **New Prostacyclin Analogues - Clinical Update on UT15, Iloprost and Beraprost**, Robyn Barst, MD, Columbia-Presbyterian Hospital, New York, NY

4:10 pm **Bosentan and Other Endothelin Blockers, Inhaled Nitric Oxide – A Clinical Update**, Richard Channick, MD, University of San Diego, San Diego, CA

4:30 pm **Preoperative Management and Workup for Pulmonary Thromboendarectomy**, Stuart W. Jamieson, MB, FRCS, University of California Medical Center, San Diego, CA

4:50 pm **Atrial Septostomy**, Keith McNeil, FRACP, Papworth Hospital, Cambridge, United Kingdom

3:30 pm-6:00 pm

**Satellite Symposium 4: Immunology Without Intimidation** (Ballroom B)

Co-Chairs: James F. George, PhD and Marlene R. Rose, PhD

3:30 pm **Overview of the Immune System**, Bruce R. Rosengard, MD, University of Pennsylvania Health Systems, Philadelphia, PA

4:00 pm **Initiation of the Antigraft Response: How Different Cell Types Interact to Produce an Immune Response: Cellular Cooperation**,

James F. George, PhD, University of Alabama at Birmingham, Birmingham, AL

4:30 pm **Effector Mechanisms: How the Immune Response Damages the Transplanted Organ**, Marlene R. Rose, PhD, Heart Science Centre, Harefield, United Kingdom

5:00 pm **How Immunosuppressive Agents Act to Inhibit the Immune Response**, Ian Hutchinson, MD, University of Manchester, Manchester, United Kingdom

3:30 pm – 6:00 pm

**Satellite Symposium 5: Pre, Intra, and Post-Op Management of Ventricular Assist Devices** (Ballroom C)

Co-Chairs: Leslie W. Miller, M.D. and Soon J. Park, M.D.

Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

Soon J. Park, MD, University of Minnesota, Minneapolis, MN

Cynthia Toher, MD, University of Minnesota, Minneapolis, MN

Guillermo Torre, MD, PhD, Baylor College of Medicine, Houston, TX

**Thursday, April 26, 2001**

**7:00 am-10:00 am**

Poster Display Session 1 Set-Up continued (Exhibit Hall C)

**7:00 am-6:30 pm**

Registration (Convention Centre Lobby)

**7:00 am-8:00 am**

Morning Coffee/Continental Breakfast (Exhibit Hall C)

**7:00 am-8:30 am**

Exhibits Open (Exhibit Hall C)

**8:00 am-10:00 am**

**OPENING PLENARY SESSION** (Hall A)

**Moderators:** Anne Keogh, MBBS, MD and David O. Taylor, MD

8:00 am **Welcome**

Anne Keogh, MBBS, MD, ISHLT President, St. Vincent's Hospital, Sydney, Australia

8:10 am **Scientific Program Report**

David O. Taylor, MD, ISHLT Scientific Program Chair, University of Utah, Salt Lake City, UT

8:15 am **Registry Report**

Jeffrey D. Hosenpud, MD, Registry Medical Director, St. Luke's Hospital, Milwaukee, WI

8:30 am **Invited Lecture: The Artificial Lung**

Brack Hattler, MD, PhD, University of Pittsburgh, Pittsburgh, PA

**Featured and Caves Candidate Abstracts**

9:00 am **(1) Sporadic Primary Pulmonary Hypertension is Caused by Germline Mutations in the Bone Morphogenetic Protein Type II Receptor**

J.R. Thomson<sup>1</sup>, R. Machado<sup>1</sup>, M. Pauciuolo<sup>2</sup>, N. Morgan<sup>1</sup>, M. Yacoub<sup>3</sup>, P. Corris<sup>4</sup>, K. McNeil<sup>5</sup>, J. Loyd<sup>6</sup>, W. Nichols<sup>2</sup>, R. Trembath<sup>1</sup>; <sup>1</sup>University of Leicester, Leicester, Leicestershire, United Kingdom; <sup>2</sup>Children's Hospital Medical Center, Cincinnati, OH; <sup>3</sup>Royal Brompton and Harefield Hospitals, Harefield, United Kingdom; <sup>4</sup>Royal Freeman Hospital, Newcastle, United Kingdom; <sup>5</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>6</sup>Vanderbilt University Medical Center, Nashville, TN

9:15 am **(2) Immunolocalisation of BMPR-II and Tgf- $\beta$  Type I and II Receptors in Primary Plexogenic Pulmonary Hypertension**

C. Atkinson<sup>1</sup>, S. Stewart<sup>1</sup>, T. Imamura<sup>2</sup>, R.C. Trembath<sup>2</sup>, N.W. Morrell<sup>1</sup>; <sup>1</sup>Papworth Hospital NHS Trust, Cambridge, United Kingdom; <sup>2</sup>Addenbrooke's Hospital, Cambridge, United Kingdom

9:30 am **(3) One Year Analysis of an Ongoing International Randomized Study of Mycophenolate Mofetil (MMF) vs Azathioprine (AZA) in Lung Transplantation**

P. Corris<sup>1</sup>, A. Glanville<sup>2</sup>, K. McNeil<sup>3</sup>, T. Wahlers<sup>4</sup>, R. Mamelok<sup>5</sup>, C. Knoop<sup>6</sup>, J. Egan<sup>7</sup>, R. Speich<sup>8</sup>, G. Martensson<sup>9</sup>, U. Svendsen<sup>10</sup>, M. Hummel<sup>11</sup>, J. Borro<sup>12</sup>, M. Carreno<sup>13</sup>, P. Morales<sup>12</sup>, A. Varela<sup>13</sup>, C. Bravo<sup>14</sup>, C. Chan<sup>15</sup>, R. Lama<sup>16</sup>, A. Roman<sup>14</sup>, A. Salvatierra<sup>16</sup>, O. Van Der Bij<sup>17</sup>, G. Verleden<sup>18</sup>, S. Bell<sup>19</sup>, L. Caubarrere<sup>20</sup>, M. Stern<sup>20</sup>, L. Eriksson<sup>21</sup>, O. Geiran<sup>22</sup>, R. Guillemain<sup>23</sup>; <sup>1</sup>University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; <sup>2</sup>St. Vincents Hospital, Sydney, Australia; <sup>3</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>4</sup>Medizinische Hochschule Hannover/Klinikum der Friedrich-Schiller-Universitat Jena, Hannover/Jena, Germany; <sup>5</sup>Roche Global Development, Palo Alto, CA; <sup>6</sup>Universite Libre de Bruxelles, Brussels, Belgium; <sup>7</sup>Wythenshawe Hospital, Manchester, United Kingdom; <sup>8</sup>Universe Hospital Zurich, Zurich, Switzerland; <sup>9</sup>Sahlgrenska Sjukhuset, Goteborg, Sweden; <sup>10</sup>Rigshospitalet, Copenhagen, Denmark; <sup>11</sup>Deutsches-Herzzentrum Berlin, Berlin, Germany; <sup>12</sup>Cirurgia Toracica Hospital La Fe, Valencia, Spain; <sup>13</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>14</sup>Hospital Vall d'Hebron, Barcelona, Spain; <sup>15</sup>The Toronto Hospital, Toronto, Canada; <sup>16</sup>Hospital Reina Sofia, Cordoba, Spain; <sup>17</sup>University Hospital Groningen, Groningen, The Netherlands; <sup>18</sup>Universitaire Ziekenhuizen Leuven, Leuven, Belgium; <sup>19</sup>Prince Charles Hospital, Chermside, Australia; <sup>20</sup>Centre Medico-Chirurgical Foch, Suresnes, France; <sup>21</sup>Universitets Sjukhuset Lund, Lund, Sweden; <sup>22</sup>Rikshospitalet, Oslo, Norway; <sup>23</sup>Hopital Broussais, Paris, France

9:45 am **(4) CTLA-4IG and Donor-Specific Transfusion Prolongs Cardiac Allograft Survival in the Miniature Swine**

R.S. Lee<sup>1</sup>, J.R. Rusche<sup>2</sup>, L.A. Cheatham<sup>2</sup>, K. Yamada<sup>1</sup>, S.L. Houser<sup>1</sup>, M.E. Maloney<sup>1</sup>, H.C. Amoah<sup>1</sup>, J.B. Mezrich<sup>1</sup>, M.H. Sayegh<sup>3</sup>, J.C. Madsen<sup>1</sup>; <sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Repligen, Needham, MA; <sup>3</sup>Brigham and Women's Hospital, Boston, MA

**10:00 am-10:30 am**

Coffee Break (Exhibit Hall C)

**10:00 am-2:00 pm**

Exhibits Open (Exhibit Hall C)

**10:30 am-Noon**

**CONCURRENT SESSION 1**

**Clinical Heart Transplantation 1: Cardiac Allograft Vasculopathy** (Hall A)

**Moderators:** Frank W. Smart, MD and Manfred Hummel, MD, PhD

10:30 am **(5) A Novel Method Based on Computerized Scoring of Rejection for the Prediction of Coronary Vasculopathy Validated by Intravascular Ultrasound**

M.H. Yamani, J.T. McMahon, J. Young, R.C. Starling, D. Cook, M. Tuzcu, P. McCarthy, N.B. Ratliff, Cleveland Clinic Foundation, Cleveland, OH

10:45 am **(6) Prognostic Value of a New Intravascular Ultrasound Score in Graft Vessel Disease**

J. Segovia<sup>1</sup>, L. Alonso-Pulpon<sup>2</sup>, J. Escaned<sup>3</sup>, F. Alfonso<sup>3</sup>, A. Flores<sup>3</sup>, A. Fernandez-Ortiz<sup>3</sup>, R. Hernandez-Antolin<sup>3</sup>, C. Bañuelos<sup>3</sup>, M. Sabate<sup>3</sup>, C. Macaya<sup>3</sup>, <sup>1</sup>Clinica Puerta de Hierro, Madrid, Spain; <sup>2</sup>Puerta de Hierro Hospital, Madrid, Spain; <sup>3</sup>Hospital Clinico, Madrid, Spain

11:00 am (7) **Haptoglobin Polymorphism Influences the Development of Cardiac Transplant Vasculopathy**  
C.G. Densem, J. Wassel, N.H. Brooks, N. Yonan, B. Keevil, Wythenshawe Hospital, Manchester, United Kingdom

11:15 am (8) **Transplant Wall Motion Analysis by Tissue Doppler Imaging in Patients With Cardiac Allograft Vasculopathy: Evaluation of Functional Severity and Timing of Follow-up Cardiac Catheterizations**  
M. Dandel, M. Hummel, E. Wellnhofer, J. Müller, R. Ewert, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany

11:30 am (9) **Are There Specific Risk Factors for Fatal Allograft Vasculopathy? An Analysis of Over 7,000 Cardiac Transplant Patients**  
M.R. Costanzo, H.J. Eisen, R.N. Brown, M. Mehra, R. Benza, G. Torre, C.W. Yancy, S. Davis, M. McCloud, J. Kirklin, CTRD at UAB, Birmingham, AL

11:45 am (10) **Coronary Atherosclerosis in Cardiac Transplant Patients Treated With Total Lymphoid Irradiation;** M.P. Pelletier, M. Coady, M. Macha, P.E. Oyer, R.C. Robbins, Stanford University, Stanford, CA

**10:30 am – Noon**

### **CONCURRENT SESSION 2**

**Donor Management, Preservation, and Organ Distribution 1: Experimental Thoracic Organ Transplantation** (Ballroom A)

**Moderators:** Shaf Keshavjee, MD, Msc, FRCSC and Stephen Large, MS, MRFP, FRCS

10:30 am (11) **In Vivo Donor Adenoviral-Mediated Transtracheal Transfection of Human IL-10 (HIL-10) Gene Ameliorates Ischemia-Reperfusion (IR) Injury and Enhances Transplanted Lung Function**

S. Fischer, M. Liu, A.A. MacLean, M. De Perrot, X. Bai, J. Cardella, Y. Imai, S. Keshavjee, University of Toronto, Toronto, Canada

10:45 am (12) **First Results 24 Hours After Orthotopic Heart Transplantation From Non-Heart-Beating Donors in Pigs**

J.R. Martin, G.F. Lutter, M.R. Siepe, S.R. Wagner, M.R. Kemper, J.R. Hilberath, K.A. Sarai, C.H. Ihling, F.R. Beyersdorf, Albert-Ludwigs-University, Freiburg, Germany

11:00 am (13) **Endothelial Function After Brain Death**

G. Szabo, V. Buhmann, C.F. Vahl, C. Sebening, S. Hagl, University of Heidelberg, Heidelberg, Germany

11:15 am (14) **Recipient Treatment With Trimetazidine Improves Graft Function and Protects the Energy Status After Lung Transplantation**

I. Inci, A. Dutly, A. Boehler, W. Weder, University Hospital, Zürich, Switzerland

11:30 am (15) **Upregulation of Bcl-2 Via Hyperbaric Pressure Transfection of TGF- $\beta$ 1 Ameliorates Ischemia/Reperfusion Injury in Rat Cardiac Allografts**

J. Grunenfelder, D. Miniati, S. Murata, M. Kown, V. Falk, E.G. Hoyt, M. Koransky, R. Robbins, Stanford University, Stanford, CA

11:45 am (16) **Improvement of Cardiac Allograft Function by 1400W, a Highly Selective Inducible Nitric Oxide Synthase Inhibitor and Superoxide Dismutase – Role of Peroxynitrite**

K. Egi<sup>1</sup>, N.E. Conrad<sup>1</sup>, A. Bedynek<sup>1</sup>, P. Ferdinandy<sup>2</sup>, B. Reichart<sup>1</sup>, S.M. Wildhirt<sup>1</sup>, <sup>1</sup>Ludwig-Maximilians University, Munich, Germany; <sup>2</sup>University of Szeged, Hungary

**10:30 am – Noon**

### **CONCURRENT SESSION 3**

**Pathology: Pathology of Heart and Lung Transplantation** (Ballroom B/C)

**Moderators:** Bruce McManus, MD, PhD and Gayle L. Winters, MD

10:30 am (17) **Biopsy Diagnosis of Disease Recurrence After Transplantation (TX) for Pulmonary Sarcoidosis: A Multicentre Study**

M. Burke<sup>1</sup>, S. Stewart<sup>2</sup>, T. Ashcroft<sup>3</sup>, C. Corbishley<sup>4</sup>, P. Bishop<sup>5</sup>, C. Kjellstrom<sup>6</sup>; <sup>1</sup>Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>3</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>4</sup>St. George's Hospital Medical School, United Kingdom; <sup>5</sup>Wythenshawe Hospital, United Kingdom; <sup>6</sup>Salgren Hospital, Goteborg, Sweden

10:45 am (18) **Interstitial Pneumonitis After Lung or Heart-Lung Transplantation in Very Young Recipients**

T.M. Hoffman, N.D. Bridges, P.A. Russo, T.L. Spray, The Children's Hospital of Philadelphia, Philadelphia, PA

11:00 am (19) **Nonimmunologic Rejection of the Heart**

C.A. Labarrere, Clarian Health Partners, Inc., Indianapolis, IN

11:15 am (20) **Anti-Thymocyte Globulin Treatment Is Associated With Complement Deposition in Early Cardiac Transplant Biopsies**

W.M. Baldwin<sup>1</sup>, L.P. Armstrong<sup>2</sup>, M.D. Samaniego<sup>1</sup>, S. Rahimi<sup>1</sup>, E.K. Kasper<sup>1</sup>, J.V. Conte<sup>1</sup>, E.R. Rodriguez<sup>1</sup>, R.H. Hruban<sup>1</sup>, <sup>1</sup>Johns Hopkins University, Baltimore, MD; <sup>2</sup>University of Virginia, Charlottesville, Virginia

11:30 am (21) **Vascular Endothelial Growth Factor-d (VEGF-d) is an Endothelial Hyperpermeability Inducing Growth Factor Differentially Expressed in Human Cardiac Allografts**

D. Wong, J. Luckhurst, H. Toma, N. Kuipers, S. Loo, A. Suarez, J.E. Wilson, B.M. Mcmanus, The University of British Columbia - St. Paul's Hospital, Vancouver, BC, Canada

11:45 am (22) **Sustained Production of the Chemokine MIG Precedes Intimal Thickening in Chronic Rejection**

J.J. Yun, M.P. Fischbein, H. Laks, M.C. Fishbein, Y. Irie, R. Strieter, J.A. Berliner, A. Ardehali, UCLA, Los Angeles, CA

**Noon-12:45 pm**

Box Lunch Pick-up (Exhibit Hall C)

**12:15 pm-1:30 pm**

**Mid-Day Workshop 1: Transplantation for the Adolescent and the Adult with Congenital Heart Disease (Hall A)**

**Moderators:** John Wallwork, MBChB, FRCS and Linda J. Addonizio, MD

**Pretransplantation Evaluation, Hemodynamic Assessment and Stabilization**, Daniel Bernstein, MD, Stanford University Medical Center, Palo Alto CA

**Perioperative Care: Technical Issues and the Benefits of a Team Approach**, Madgi Yacoub, MD, Royal Brompton Hospital, Royal Brompton Hospital, London, United Kingdom

**Post-Transplant Outcomes**, Jacqueline M. Lamour, MD, Columbia-Presbyterian Medical Center, New York,

**12:15 pm-1:45 pm**

**Mid-Day Workshop 2: Immunosuppressive Protocols and Drug Monitoring: Defend or Deny (Ballroom B/C)**

**Moderators:** Bruno M. Meiser, MD and Jon Kobashigawa, MD

Jon Kobashigawa, MD, UCLA Medical Center, Los Angeles, CA

Bruno M. Meiser, MD, Grosshadern Medical Center, Munich, Germany

Randall C. Starling, MD, Cleveland Clinic Foundation, Cleveland, OH

Ainat Beniaminovitz, MD, Columbia-Presbyterian Hospital, New York, NY

Gunther Laufer, MD, University Hospital Innsbruck, Innsbruck, Austria

Mauro Rinaldi, MD, Pavia, Italy

**12:15 pm-1:45 pm**

**Mid-Day Workshop 3: Core Curriculum: Thoracic Transplant Pathology: Under the Scope (Ballroom A)**

Henry D. Tazelaar, MD, Mayo Clinic, Rochester, MN

Michael C. Fishbein, MD, University of California at Los Angeles, Los Angeles, CA

**12:15 pm-1:45 pm**

**Mini Oral Poster Presentation Session 1 (Rooms 8 & 15)**

**Moderators:** Willem Weimar, MD and Joren C. Madsen, MD, D.Phil.

**12:15 pm (23) Early T Lymphocyte Trafficking After Allo-Transplantation**

J. Legare, G.M. Hirsch, T.B. Issekutz, Dalhousie University, Halifax, Nova Scotia, Canada

**12:21 pm (24) A Novel Scavenger of Nitric Oxide Decreases Heme Protein Nitrosylation and Prolongs Graft Survival During Cardiac Transplant Rejection**

G.M. Pieper, A.M. Roza, M.B. Adams, M. Johnson, G. Hilton, C.C. Felix, S.P. Fricker; Medical College of Wisconsin, Milwaukee, WI

**12:27 pm (25) IL-4 Promoter Gene Polymorphism in Heart Transplantation**

F. Bijlsma, J. Van Kuik, N. De Jonge, M. Tilanus, A. Bruggink, F. Gmelig Meyling, R. De Weger, University Medical Center, Utrecht, The Netherlands

**12:33 pm (26) Matrixmetalloproteinase (MMP) 9 Activity and Impaired Coronary Vasomotor Function After Cardiac Transplantation in Rats**

S.M. Wildhirt<sup>1</sup>, K. Egi<sup>1</sup>, J.A. Kwan<sup>2</sup>, N.E. Conrad<sup>1</sup>, C.J. Schulze<sup>2</sup>, R. Schulz<sup>2</sup>, B. Reichart<sup>1</sup>; <sup>1</sup>Ludwig-Maximilians University, Munich, Germany; <sup>2</sup>University of Alberta, Edmonton, Canada

**12:39 pm (27) Indirect Allorecognition and Alloantibody Production Precede Obliterative Airway Disease Development After Tracheal Transplantation in Mice**

M. Smith, K. Sivasai, B. Naziruddin, Z. Kaleem, G. Patterson, T. Mohanakumar, Washington University School of Medicine, St. Louis, MO

**12:45 pm (28) Lung Transplantation for Cystic Fibrosis; the Effect of B Cell Depletion on Post Transplant Outcomes**

A. De Soyza<sup>1</sup>, L.N. Archer<sup>1</sup>, A.N. McDowell<sup>2</sup>, J.N. Moore<sup>3</sup>, J.H. Dark<sup>4</sup>, S.N. Elborn<sup>2</sup>, E.N. Mahenthalingam<sup>5</sup>, P.A. Corris<sup>4</sup>, K.N. Gould<sup>1</sup>; <sup>1</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>Belfast City Hospital, Belfast, Northern Ireland United Kingdom; <sup>3</sup>Belfast City Hospital, Belfast, Northern Ireland, United Kingdom; <sup>4</sup>University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom; <sup>5</sup>University of Wales at Cardiff, Cardiff, Wales, United Kingdom

**12:51 pm (29) Oxidative Stress of Cardiac Transplantation is Associated With Decreased BCL-2 Expression and Increased NFkB Activity**

D.N. Miniati, J. Grunenfelder, E.G. Hoyt, S. Murata, M. Kown, M. Koransky, R. Robbins, Stanford University, Stanford, CA

**12:57 pm (30) Impairment of Cytolytic Activity in Allograft Environment Affects Early Medial Cell Loss but Does not Alter Outcome of Allograft Arteriosclerosis**

J.L. O'Neill, J.L. Jordan, J. Zhou, T.D. Lee, G.M. Hirsch, Dalhousie University, Halifax, NS, Canada

**1:03 pm (31) Elevation of Serum Big Endothelin is Associated With Endothelial Dysfunction in Patients With Chronic Heart Failure**

R. Berger, K. Strecker, B. Stanek, M. Huelsmann, R. Pacher, T. Neunteufl, University of Vienna, Vienna, Austria

**1:09 pm (32) Tumour Necrosis Factor- A A2 Polymorphism; A Predisposing Factor to Non-Ischaemic Myocardial Dysfunction?**



C. Densem<sup>1</sup>, I.V. Hutchinson<sup>2</sup>, N. Yonan<sup>1</sup>, N.H. Brooks<sup>1</sup>, <sup>1</sup>Wythenshawe Hospital, Manchester, United Kingdom; <sup>2</sup>Manchester University, Manchester, United Kingdom

1:15 pm (33) **A Dominant Negative Isoform of the Serum-Response Factor (SRF) is Increased in the Failing Human Heart**  
M. Gupta, F.J. Davis, D. Jayakar, V. Jeevananadam, The University of Chicago, Chicago, IL

1:21 pm (34) **The Effects of Mycophenolate Mofetil on Cardiac Allograft Survival and Cardiac Allograft Vasculopathy in Miniature Swine**  
M.L. Schwarze, J.D. Mezrich, M.T. Menard, S.L. Houser, M.E. Maloney, E.P. Pillsbury, D.H. Sachs, J.C. Madsen, Massachusetts General Hospital, Boston, MA

1:27 pm (35) **Co-Administration of Tacrolimus and Mycophenolate Mofetil Does not Increase Mycophenolic Acid (MPA) Exposure, But Co-Administration of Cyclosporine Inhibits the Enterohepatic Recirculation of MPA, Thereby Decreasing its Exposure**  
T. Van Gelder<sup>1</sup>, J. Klupp<sup>2</sup>, M.J. Barten<sup>2</sup>, U. Christians<sup>3</sup>, R.E. Morris<sup>2</sup>, <sup>1</sup>University Hospital Rotterdam, Rotterdam, The Netherlands; <sup>2</sup>Stanford University, Stanford, CA; <sup>3</sup>UCSF, San Francisco, CA

1:33 pm (36) **ISATX247: A Novel Calcineurin Inhibitor**  
M.D. Abel<sup>1</sup>, L.J. Aspeslet<sup>1</sup>, D.G. Freitag<sup>1</sup>, S. Naicker<sup>1</sup>, D.J. Trepanier<sup>1</sup>, N.M. Kneteman<sup>2</sup>, R.T. Foster<sup>1</sup>, R.W. Yatscoff<sup>1</sup>, <sup>1</sup>Isotechnika Inc., Edmonton, AB, Canada; <sup>2</sup>University of Alberta, Edmonton, AB, Canada

1:39 pm (37) **Eotaxin and Prednisolone Concentrations Regulate the Mobilisation of Peripheral Blood Eosinophils Preceding Heart Allograft Rejection**  
A.K. Trull, S.C. Charman, S. Endenburg, F. Akhlaghi, O. Majid, J. Cornelissen, L.D. Sharples, L.A. Steel, J. Parameshwar, J. Wallwork, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**2:00 PM-3:30 PM**

#### **CONCURRENT SESSION 4**

**Immunosuppression 1: Clinical Outcome Measurements and Side Effects (Hall A)**

**Moderators:** Bruno M. Meiser, MD and Jon Kobashigawa, MD

2:00 pm (38) **Cyclosporine Versus Tacrolimus in Heart Transplantation: An ISHLT/UNOS Registry Analysis**  
J.D. Hosenpud<sup>1</sup>, L.E. Bennett<sup>2</sup>, <sup>1</sup>St. Lukes Medical Center, Milwaukee, WI; <sup>2</sup>United Network for Organ Sharing, Richmond, VA

2:15 pm (39) **Current Practices: Immunosuppression Induction, Maintenance and Rejection Regimens in 213 Consecutive Transplant Recipients**

A. Gass<sup>1</sup>, H. Eisen<sup>2</sup>, B. Griffith<sup>3</sup>, J. Kobashigawa<sup>4</sup>, M. Koerner<sup>5</sup>, D. Mancini<sup>6</sup>, M. Mehra<sup>7</sup>, B. Meiser<sup>8</sup>, S. Webber<sup>9</sup>, J. Young<sup>10</sup>, E. Gilb<sup>11</sup>, S. Tuteja<sup>11</sup>, <sup>1</sup>Mount Sinai Medical Center, New York, NY; <sup>2</sup>Temple University School of Medicine, Philadelphia, PA; <sup>3</sup>University of Pittsburgh Medical Center, Pittsburgh, PA; <sup>4</sup>UCLA, Los Angeles, CA; <sup>5</sup>Baylor College of Medicine, Houston, TX; <sup>6</sup>Columbia Presbyterian Medical Center, New York, NY; <sup>7</sup>Ochsner Medical Institutions, New Orleans, LA; <sup>8</sup>University of Munich, Munich, Germany; <sup>9</sup>Childrens Hospital of Pittsburgh, Pittsburgh, PA; <sup>10</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>11</sup>Cincinnati Transplant Institute, Cincinnati, OH

2:30 pm (40) **Early Experience With Sirolimus in Lung Transplant Recipients**

B. Cahill, J. Crompton, T. Somerville, M. O'Rourke, S. Parker, J. Stringham, S. Karwande, University of Utah, Salt Lake City, UT

2:45 pm (41) **Pharmacodynamic (PD) Measurements of the Immunosuppressive Effects of the Combination of Cyclosporine (Cy) and Mycophenolate Mofetil (MMF): Correlation Between Drug Dose and Lymphocyte Function**

J.F. Gummert, M.J. Barten, P. Bartsch, M. Boeger, P. Gelhaar, T. Rauch, R. Autschbach, F.W. Mohr, Heart Center Leipzig, Leipzig, Germany

3:00 pm (42) **Benefit of Mycophenolate-Mofetil (MMF) in Patients With Cyclosporine (CyA) Induced Nephropathy After Cardiac Transplantation**

A. Zuckermann, M. Ploner, Ü. Keziban, M. Czerny, E. Wolner, G. Laufer, M. Grimm, University of Vienna, Vienna, Austria

3:15 pm (43) **Sirolimus (Rapamycin) Allows Renal Recovery in Lung and Heart Transplant Recipients With Chronic Renal Impairment**  
G.I. Snell<sup>1</sup>, B. Levvey<sup>1</sup>, W. Chin<sup>2</sup>, M. Richardson<sup>1</sup>, T. Kotsimbos<sup>1</sup>, H.M. Whitford<sup>1</sup>, T.J. Williams<sup>1</sup>, <sup>1</sup>Alfred Hospital, Melbourne, Australia; <sup>2</sup>Sir Charles Gairdner Hospital, Perth, Australia

**2:00 pm-3:30 pm**

#### **CONCURRENT SESSION 5**

**Clinical Heart Failure 1: Outcomes: Relevance to Selecting Heart Transplant Candidates (Ballroom A)**

**Moderators:** Robert E. Hobbs, MD and Debra L. Isaac, MD

**Invited Lecture: Predicting Outcome in Patients with Heart Failure**, Keith Aaronson, MD, University of Michigan Medical Center, Ann Arbor, MI

2:15 pm (44) **Clinical Value of Brain Natriuretic Peptide for Candidate Selection Before Cardiac Transplantation**

J. Koglin, S. Pehlivanli, M. Schwaiblmair, M. Vogeser, P. Cremer, W. Von Scheidt, Universitaetsklinikum Grosshadern, University of Munich, Munich, Germany

2:30 pm (45) **Relationship Between Peak Exercise Oxygen Consumption and QTC in Patients With Advanced Heart Failure**

F. Boccacalandro, A. Yepes, A. Velasco, C.D. Thomas, M. Bologna, B. Richartz, B. Radovancevic, Texas Heart Institute, Houston, TX

2:45 pm (46) **Does Hyperuricemia Predict Adverse Clinical Outcome While Awaiting Heart Transplantation?**

P.A. Uber, M.R. Mehra, M.H. Park, H. Ventura, R.L. Scott, Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA

3:00 pm (47) **Does HDL-Cholesterol Level Predict Clinical Outcome in Advanced Heart Failure?**

M.R. Mehra, P.A. Uber, M.H. Park, R.L. Scott, R.V. Milani, Ochsner Clinic, New Orleans, LA

**3:15 pm (48) Predicting a Patient's Waiting Time to Heart Transplant in the UK**

F.M. Seeney<sup>1</sup>, J. Mahler<sup>1</sup>, L. Sharples<sup>2</sup>, J. Parameshwar<sup>2</sup>; <sup>1</sup>UK Transplant, Bristol, United Kingdom; <sup>2</sup>Papworth Hospital, Cambridge, United Kingdom

**2:00PM - 3:30PM**

**CONCURRENT SESSION 6**

**Basic Science and Immunobiology 1: Chronic Lung Rejection (Ballroom B/C)**

**Moderators:** Marlene R. Rose, MD and James S. Allan, MD

**2:00 pm (49) Indirect Alloresponses are More Pronounced in Non-Rejecting Lung Than Heart Allografts**

S.A. Webber, C. Bentejeweski, G.J. Boyle, Y. Law, P. Bowman, S.A. Miller, S. Gribar, A. Fitzsimmons, K. Mccurry, S. Murali, B. Griffith, A. Zeevi, University of Pittsburgh, Pittsburgh, PA

**2:15 pm (50) Binding of Anti-HLA Class I Antibodies to Airway Epithelial Cells Induces Activation and Growth Factor Production and Indirectly Upregulates Lung Fibroblast Proliferation**

A. Jaramillo, L. Zhang, T. Mohanakumar, Washington University School of Medicine, St. Louis, MO

**2:30 pm (51) Recipient Cells Form the Proliferative Lesion in the Rat Heterotopic Tracheal Allograft Model of Obliterative Airway Disease (OAD)**

J.L. Jordan, C.L. Hurley, T.D. Lee, G.M. Hirsch, Dalhousie University, Halifax, Nova Scotia, Canada

**2:45 pm (52) Neutralization of Tumor Necrosis Factor-alpha or Interleukin-1 Prevents Obliterative Airway Disease in HLA-A2 Transgenic Murine Tracheal Allografts**

C. Smith, A. Jaramillo, K.C. Lu, Z. Kaleem, G. Patterson, T. Mohanakumar, Washington University School of Medicine, St. Louis, MO

**3:00 pm (53) Blockade of PDGF Receptor Protein-Tyrosine Kinase Activity Effectively Inhibits Development of Rat CMV Infection Enhanced Experimental Obliterative Bronchiolitis**

J.M. Tikkanen<sup>1</sup>, K. Lemstrom<sup>2</sup>, P.K. Koskinen<sup>2</sup>; <sup>1</sup>University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland; <sup>2</sup>Transplantation Laboratory, Helsinki, Finland

**3:15 pm (54) Cell-Mediated Immunity to Collagen V in Lung Transplant Recipients: Correlation With Collagen V Release Into BAL Fluid**

D.S. Wilkes<sup>1</sup>, K.M. Heidler<sup>1</sup>, K. Yasufuku<sup>1</sup>, L. Devito-haynes<sup>2</sup>, E. Jankowska-gan<sup>3</sup>, K.C. Meyer<sup>2</sup>, R.B. Love<sup>2</sup>, W.J. Burlingham<sup>4</sup>; <sup>1</sup>Indiana University, Indianapolis, IN; <sup>2</sup>University of Wisconsin School of Medicine, Madison, WI; <sup>3</sup>University of Wisconsin School of Medicine, Mazomanie, WI

**4:00PM - 5:30PM**

**CONCURRENT SESSION 7**

**Clinical Heart Transplantation 2: Clinical Outcomes (Hall A)**

**Moderators:** Barry K. Rayburn, MD and Gunther Laufer, MD

**4:00 pm (55) The Emergence of Co-Morbid Diseases Impacting Survival After Cardiac Transplantation, A Ten Year Multi-Institutional Experience**

R.C. Bourge<sup>1</sup>, J.K. Kirklin<sup>2</sup>, K. Thomas<sup>2</sup>, B. Czerska<sup>2</sup>, F. Lee<sup>2</sup>, E.K. Kasper<sup>2</sup>, L. Waggoner<sup>2</sup>, J.P. Boehmer<sup>2</sup>, J.A. Hill<sup>2</sup>, D.C. Naftel<sup>2</sup>, Cardiac Transplant Research Database<sup>2</sup>; <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL; <sup>2</sup>CTRD at UAB, Birmingham, AL

**4:15 pm (56) Short-Term Survival With Combined Heart-Kidney or Combined Heart-Liver Transplantation With Allografts From a Single Donor**

S. Murali, T. Tokarczyk, J. Ristich, K. McCurry, G.A. MacGowan, W.D. Rosenblum, D.M. Mcnamara, R. Shapiro, J.J. Fung, R.L. Kormos, <sup>1</sup>University of Pittsburgh, Pittsburgh, PA

**4:30 pm (57) Survival of Diabetic Patients Following Cardiac Transplant**

D. Mancini, A. Beniaminovitz, N. Edwards, J. Chen, S. Maybaum, Columbia University, New York, NY

**4:45 pm (58) Who is Most Likely to Enjoy Long Term Survival After Cardiac Transplantation? Risk Stratification in a 10 Year Multi-Institutional Experience**

J. Kirklin, L.W. Miller, R.N. Brown, R.J. Alvarez, C.B. Porter, A.B. Vanbakel, B.E. Jaski, T. Wannenburg, C. White-Williams, R.C. Bourge, CTRD at UAB, Birmingham, AL

**5:00 pm (59) Heart Transplantation in Friedreich's Ataxia and Other Neuromuscular Diseases**

J. Segovia, L. Alonso-Pulpon, R. Burgos, L. Silva, S. Serrano, E. Castedo, J. Jiménez, R. Fuentes, A. Cañas, J. Ugarte, Puerta de Hierro Hospital, Madrid, Spain

**5:15 pm (60) Functional Relevance of Sympathetic Reinnervation for the Transplanted Heart**

P. Ueberfuhr<sup>1</sup>, F. Bengel<sup>2</sup>, N. Schiepel<sup>2</sup>, M. Schwaiger<sup>2</sup>, B. Reichart<sup>1</sup>; <sup>1</sup>Klinikum Grosshadern, LMU, München, Germany; <sup>2</sup>Technische Universität Muenchen, Muenchen, Germany

**4:00PM - 5:30PM**

**CONCURRENT SESSION 8**

**Lung/Heart-Lung Transplantation 1: Viral Infections (Ballroom A)**

**Moderators:** Marshall I. Hertz, MD and Jim J. Egan, MD

4:00 pm **(61) Community Acquired Respiratory Viruses in Lung Transplant Patients: Incidence and Outcomes**  
T.N. Hodges, F.P. Torres, J. Marqueson, M. Diercks, M.R. Zamora, University of Colorado Health Sciences Center, Denver, CO

4:15 pm **(62) Direct Fluorescent Antibody Testing in the Diagnosis of Influenzae Infection in Lung Transplant Recipients**  
P.M. Hopkins, M. Plit, I. Cater, P. Chhajed, M. Malouf; A. Glanville, St. Vincent's Hospital, Sydney, Australia

4:30 pm **(63) Treatment of Respiratory Syncytial Viral and Parainfluenza Lower Respiratory Tract Infection in Lung Transplant Patients**  
T.N. Hodges, F.P. Torres, M.R. Zamora, University of Colorado Health Sciences Center, Denver, CO

4:45 pm **(64) Incidence of Bronchiolitis Obliterans Syndrome Unaffected by Absence of Cytomegalovirus**  
H. Luckraz, L.D. Sharples, K. McNeil, J. Wallwork, Papworth Hospital NHS Trust, Cambridge, United Kingdom

5:00 pm **(65) Bronchiolitis Obliterans With Organizing Pneumonia: Possible Association With Human Herpes Virus-7 Infection After Lung Transplantation**  
D.J. Ross<sup>1</sup>, R.C. Chan<sup>2</sup>, B. Kubak<sup>1</sup>, A. Ardehali<sup>1</sup>, H. Laks<sup>1</sup>, W.S. Nichols<sup>2</sup>; <sup>1</sup>University of California at Los Angeles, Los Angeles, CA; <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, CA

5:15 pm **(66) Chlamydia Pneumoniae is Associated With Graft Dysfunction After Lung Transplantation**  
A.R. Glanville, M. Gencay, M. Tamm, M. Plit, P. Chhajed, P. Hopkins, C. Aboyoun, S. Rainer, M. Roth, M. Malouf; St Vincent's Hospital, Sydney, Australia

## **CONCURRENT SESSION 9**

**4:00PM - 5:30PM**

**Basic Science and Immunobiology 2: Tolerance and the Endothelium** (Ballroom B/C)

**Moderators:** James F. George, PhD and George Tellides, MD

4:00 pm **(67) Endothelial-Cell Selective CTL Arise From Limited Precursor Subsets of Alloreactive CD8+ T Cells and Show Reduced Clonal Expansion**  
T.J. Dengler<sup>1</sup>, D.R. Johnson<sup>2</sup>, J. Pober<sup>2</sup>, <sup>1</sup>Medinische Universitaetsklinik, Heidelberg, Germany; <sup>2</sup>BCMM, New Haven, CT

4:15 pm **(68) Differential Modulation of Alloreactive T Cell Receptor Expression Induced by Allogeneic Bone Marrow and Splenocyte Infusions**  
J.F. George, L. Ahumada, T. Chang, J.K. Kirklín, J.M. Thomas, University of Alabama at Birmingham, Birmingham, AL

4:30 pm **(69) The Role of Indirect Recognition of Donor MHC Class II Peptides in Cardiac Transplantation in Miniature Swine**  
R.S. Lee<sup>1</sup>, K.L. Womer<sup>2</sup>, K. Yamada<sup>1</sup>, M.E. Maloney<sup>1</sup>, S.L. Houser<sup>1</sup>, M.H. Sayegh<sup>2</sup>, J.C. Madsen<sup>1</sup>, <sup>1</sup>Massachusetts General Hospital, Boston, MA; <sup>2</sup>Brigham and Women's Hospital, Boston, MA

4:45 pm **(70) Mechanisms of Tolerance Induction in the Heart/Kidney Model in Miniature Swine**  
J.D. Mezrich, K. Yamada, R.S. Lee, K. Mawulawde, S.L. Houser, M.L. Schwarze, M.E. Maloney, H.C. Amoah, E.P. Pillsbury, D.H. Sachs, J.C. Madsen, Massachusetts General Hospital, Boston, MA

5:00 pm **(71) Peripheral Expansion of Circulating Th1 Cells Predicts Coronary Endothelial Dysfunction After Cardiac Transplantation**  
J. Koglin<sup>1</sup>, H. Methe<sup>1</sup>, B. Meiser<sup>1</sup>, W. Von Scheidt<sup>1</sup>, M.E. Russell<sup>2</sup>, <sup>1</sup>Universitaetsklinikum Grosshadern, University of Munich, Munich, Germany; <sup>2</sup>Harvard School of Public Health, Boston, MA

5:15 pm **(72) Neonatal Infusion of Allogeneic Fetal Liver Cells Induces Non-Specific Acceptance of Cardiac Allografts Without Diminution of Alloreactivity to Skin Grafts and In Vitro Assays**  
L.J. West, K. Tao, Hospital for Sick Children/University of Toronto, Toronto, ON, Canada

**5:30 pm - 6:30 pm**

**Moderated Poster Session 1/Wine and Cheese Reception** (Exhibit Hall C)

**(Please see page ??? of this program booklet for the list of Poster Session 1 titles and authors - Abstracts 73 – 141)**

**6:30 pm–7:30 pm**

Poster Display Session 1 Tear-Down (Exhibit Hall C)

**7:30 pm-10:00 pm**

President's Gala Reception (Pan Pacific Hotel Atrium)

## **FRIDAY, APRIL 27, 2001**

**6:30 am-5:00 pm**

Registration (Convention Centre Lobby)

**6:30 am-8:00 pm**

Morning Coffee/Continental Breakfast (Exhibit Hall C)

**6:30 am - 8:30 am**

Exhibits Open (Exhibit Hall C)

**6:30 am-10:00 am**

Poster Display Session 2 Set-Up (Exhibit Hall C)

**6:45 am-7:45 am**

**Sunrise Symposium 1: Issues in Allograft Vasculopathy** (Rooms 8 & 15)

**Moderators:** Robert S.D. Higgins, MD and Hannah A. Valentine, MD

**Accelerated Vasculopathy: Introduction, Incidence, Diagnosis and Treatment**

Robert S.D. Higgins, MD, Medical College of Virginia, Richmond, VA

**Vasculopathy as a Consequence of Metabolic Disturbance**

Hannah A. Valentine, MD, Stanford University School of Medicine, Stanford, CA

**Induction vs. Non-Induction Immunotherapy –Can It Impact Vasculopathy?**

Andreas O. Zuckerman, MD, University of Vienna, Austria, Vienna

**6:45 AM-7:45 am**

**Sunrise Symposium 2: Would You Use This Lung Donor?** (Ballroom A)

**Moderators:** Gregory I. Snell, FRACP, MBBS and Duane Davis, MD

Shaf Keshavjee, MD, Toronto General Hospital, Toronto, Canada

Robert B. Love, MD, University of Wisconsin Hospitals, Madison, WI

Bruce R. Rosengard, MD, University of Pennsylvania, Philadelphia, PA

**6:45 AM-7:45 am**

**Sunrise Symposium 3: More VADs Gone Bad** (Hall A)

**Moderators:** O.H. Frazier, MD and Mehmet C. Oz, MD

Francisco A. Arabia, MD, University of Arizona Health Science Center, Tucson, AZ

Michael A. Acker, MD, University of Pennsylvania, Philadelphia, PA

Aly El-Banayosy, MD, Ruhr-Universität Bochum, Bad Oeynhausen, Germany

Michael K. Banbury, MD, Cleveland Clinic Foundation, Cleveland, OH

**6:45 am-7:45 am**

**Sunrise Symposium 4: Anything But a Heart Biopsy: Noninvasive Rejection Detection** (Ballroom B/C)

**Moderators:** Jignesh K. Patel, MD, PhD and Hermann Reichenspurner, MD, PhD

Magnetic Resonance Imaging, Mandeep R. Mehra, MD, Ochsner Medical Institutions, New Orleans, LA

Intramyocardial Electrocardiograms, Florian Iberer, MD, University of Graz, Graz, Austria

Cyto-Immunological Monitoring, Claus Hammer, MD, University of Munich Institute for Surgical Research, Munich, Germany

Echocardiography, Stuart D. Russell, MD, Duke University, Durham, NC

Breath Testing, Jignesh K. Patel, MD, PhD, University of California at Los Angeles, Los Angeles, CA

**8:00 am-10:00 am**

**PLENARY SESSION** (Hall A)

**Moderators:** Robert L. Kormos, MD and Alan H. Menkis, MD, FRCS(C)

8:00 am **Presidential Address**

Anne Keogh, MBBS, MD, ISHLT President, St. Vincent's Hospital, Sydney, Australia

8:30 am **Invited Lecture: Cell Transplantation: Progress in Patients?**

Doris A. Taylor, MD, Duke University Medical Center, Durham, NC

**Featured and Caves Candidate Abstracts**

9:00 am **(142) Acute and Chronic Onset of Bronchiolitis Obliterans Syndrome (BOS): Are They Different Entities?**

L.D. Sharples<sup>1</sup>, C.H. Jackson<sup>2</sup>, K. McNeil<sup>1</sup>, J. Wallwork<sup>1</sup>, <sup>1</sup>Papworth Hospital NHS Trust, Cambridge, United Kingdom; <sup>2</sup>MRC Biostatistics Unit, Cambridge, United Kingdom

9:15 am **(143) A Murine Model of Left Ventricular Tissue Engineering**

A.S. Krupnick, D. Kreisel, W.Y. Szeto, S.H. Popma, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

9:30 am **(144) The Growth Enhancing Effects of Allograft Inflammatory Factor-1 (AIF-1) in Vsmc are Dose-Dependent and Mediated by its Ability to Bind Calcium**

M.V. Autieri, C.J. Carbone, H. Eisen, Temple University School of Medicine, Philadelphia, PA

9:45 am **(145) Association of Viral Genome With Transplant Coronary Arteriopathy and Graft Loss in Children Following Cardiac Transplantation/Viral Genome in the Myocardium and Outcomes in Heart Transplant Recipients**

N.E. Bowles<sup>1</sup>, G.S. Shirali<sup>2</sup>, R.E. Chinnock<sup>3</sup>, G.L. Rosenthal<sup>4</sup>, J.A. Towbin<sup>1</sup>, B. Radovancevic<sup>5</sup>, C. D. Thomas<sup>5</sup>, O. H. Frazier<sup>5</sup>, V.

Thuy<sup>1,4</sup> Baylor College of Medicine, Houston, TX; <sup>2</sup>Medical University of South Carolina, Charleston, SC; <sup>3</sup>Loma Linda University Children's Hospital, Loma Linda, CA; <sup>4</sup>University of Washington, Seattle, WA; <sup>5</sup>Texas Heart Institute, Houston, TX

**10:00 am-10:30 am**

Coffee Break (Exhibit Hall C)

**10:00 am-2:00 pm**

Exhibits Open (Exhibit Hall C)

**10:30 am-Noon**

**CONCURRENT SESSION 10**

**Lung/Heart-Lung Transplantation 2: Post-Transplant Lymphoproliferative Disorders and Epstein Barr Virus (Hall A)**

**Moderators:** Vincent G. Valentine, MD and Annette Boehler, MD

10:30 am (146) **Donor or Recipient Origin of Post Transplant Lymphoproliferative Disease After Lung Transplantation;** E.A. Verschuuren, E.R. Popa, W. Van Der Bij, M.C. Harmsen, T.H. The, B. Hepkema, University Hospital Groningen, Groningen, The Netherlands

10:45 am (147) **EBV Mismatching and HLA Matching Post Lung Transplantation: Key Risk Factors for Post Transplant Lymphoproliferative Disease and (PTLD)**

J.Y. Wong, B. Tait, B. Levvey, A. Griffiths, D.S. Esmore, G.I. Snell, T.J. Williams, T.C. Kotsimbos, Alfred Hospital, Melbourne, Australia

11:00 am (148) **Patients at Risk for Post-Transplant Lymphoproliferative Disease can be Identified in the First Months After Lung Transplantation by Quantitative-Competitive-EBV-PCR;** E.A. Verschuuren

S. Stevens, B.B. Hanekamp, C. De Boer, M.C. Harmsen, J.M. Middeldorp, G. Koeter, T.H. The, W. Van Der Bij, University Hospital, Groningen, The Netherlands

11:15 am (149) **Frequent Monitoring of Epstein-Barr Virus DNA Load in Unfractionated Whole Blood is Essential for Early Detection of Post-Transplant Lymphoproliferative Disease in Lung Transplant Patients**

E.A. Verschuuren<sup>1</sup>, S. Stevens<sup>2</sup>, I. Pronk<sup>2</sup>, W. Van Der Bij<sup>1</sup>, M.C. Harmsen<sup>1</sup>, T.H. The<sup>1</sup>, C.J. Meijer<sup>2</sup>, A.J. Van Den Brule<sup>2</sup>, J.M. Middeldorp<sup>2</sup>,<sup>1</sup>University Hospital, Groningen, The Netherlands; <sup>2</sup>Free University, Amsterdam, The Netherlands

11:30 am (150) **Antiviral Prophylaxis Prevents Lymphoproliferative Disease in Lung Transplant Recipients**

M.A. Malouf, P.N. Chhajed, P. Hopkins, M.L. Plit, A. Glanville, St Vincents Hospital, Sydney, Australia

11:45 am (151) **Monthly Infusion of Cytomegalovirus Immune Globulin (CMVIG) Decreases the Incidence of Bacterial and Fungal Infections in the First Year Following Lung Transplantation**

M.R. Zamora, F. Torres, J. Marquesan, M. Diercks, T. Hodges, University of Colorado Health Sciences Center, Denver, CO

**CONCURRENT SESSION 11**

**10:30 am-Noon**

**Mechanical and Circulatory Support 1: Clinical Experience with Mechanical Ventricular Support and Optional Weaning from LVAD (Ballroom A)**

**Moderators:** George Wieselthaler, MD and Benjamin C. Sun, MD

10:30 am (152) **Clinical Experience With Nine Patients Supported by the Continuous Flow DeBakey VAD™**

M.J. Wilhelm<sup>1</sup>, D. Hammel<sup>1</sup>, C. Schmid<sup>1</sup>, J. Stypmann<sup>1</sup>, B. Asfour<sup>1</sup>, D. Kemper<sup>1</sup>, C. Schmidt<sup>1</sup>, D. Morley<sup>2</sup>, G.P. Noon<sup>3</sup>, M.E. DeBakey<sup>3</sup>, H.H. Scheld<sup>1</sup>,<sup>1</sup>University of Muenster, Muenster, Germany; <sup>2</sup>MicroMed Technology, Inc., Houston, TX; <sup>3</sup>Texas Medical Center, Houston, TX

10:45 am (153) **Initial Experience With the Jarvik 2000 Left Ventricular Assist System as a Bridge to Transplantation: Report of 4 Cases**  
O.H. Frazier<sup>1</sup>, I.D. Gregoric<sup>1</sup>, R.M. Delgado<sup>1</sup>, T.J. Myers<sup>1</sup>, B. Radovancevic<sup>1</sup>, T. Khan<sup>1</sup>, K. Miller<sup>1</sup>, J.K. Ho<sup>1</sup>, R.K. Jarvik<sup>2</sup>,<sup>1</sup>Texas Heart Institute, Houston, TX; <sup>2</sup>Jarvik Heart Inc, New York, NY

11:00 am (154) **Multicenter Clinical Evaluation of the Heartmate® Vented Electric Left Ventricular Assist System in Patients Awaiting Heart Transplantation**

O.H. Frazier<sup>1</sup>, E.A. Rose<sup>2</sup>, M.C. Oz<sup>3</sup>, W.P. Dembitsky<sup>4</sup>, P.M. McCarthy<sup>5</sup>, B. Radovancevic<sup>1</sup>, V.L. Poirier<sup>6</sup>, K.A. Dasse<sup>7</sup>,<sup>1</sup>Texas Heart Institute, Houston, TX; <sup>2</sup>Columbia University, New York, NY; <sup>3</sup>Columbia-Presbyterian Medical Center, New York, NY; <sup>4</sup>Sharp Memorial Hospital, San Diego, CA; <sup>5</sup>Cleveland Clinic Foundation, Cleveland, OH; <sup>6</sup>Thermo Cardiosystems, Inc., Woburn, MA; <sup>7</sup>Tharos, LLC, Waltham, MA

11:15 am (155) **Predictive Factors for Weaning From a Cardiac Assist Device. An Analysis of Clinical, Gene Expression and Protein Data**  
J. Mueller<sup>1</sup>, G. Wallukat<sup>1</sup>, Y. Weng<sup>1</sup>, M. Dandel<sup>1</sup>, P. Ellinghaus<sup>2</sup>, J. Huetter<sup>2</sup>, R. Hetzer<sup>1</sup>,<sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Bayer AG, Wuppertal, Germany

11:30 am (156) **Does Unloading the Heart by a Left Ventricular Assist Device Result in Sustained Reversal of Myocyte Dysfunction in End-Stage Heart Failure?**

N. De Jonge, D.F. Van Wichem, M.E. Schipper, J.R. Lahpor, F.H. Gmelig-Meyling, R.A. De Weger, University Medical Center, Utrecht, The Netherlands

11:45 am (157) **Assessment of Myocardial Recovery Using Dobutamine Stress Echocardiography in LVAD Patients**

T. Khan, K. Okerberg, A. Hernandez, K. Miller, T.J. Myers, B. Radovancevic, R.M. Delgado, I. Gregoric, O.H. Frazier, Texas Heart Institute, Houston, TX

**CONCURRENT SESSION 12**

**10:30am-Noon**

**(12) Nursing, Social Sciences, and Healthcare Economics (Ballroom B/C)**

**Moderators:** Sandra A. Cupples, DNSc and Wayne D. Paris, MSW

10:30 am **(158) Long-Term Post-Transplant Quality of Life Outcomes in Patients Bridged to Transplant With Ventricular Assist Devices**  
M.A. Dew, R.L. Kormos, S. Winowich, E. Stanford, L. Carozza, B.P. Griffith; University of Pittsburgh, Pittsburgh, PA

10:45 am **(159) Change in Physical and Psychosocial Domains of Quality of Life From Before to After Discharge Post Left Ventricular Assist Device Implantation**  
K.L. Grady<sup>1</sup>, P. Meyer<sup>1</sup>, A. Mattea<sup>1</sup>, D. Dressler<sup>2</sup>, S. Ormaza<sup>3</sup>, C. White-Williams<sup>4</sup>, S. Chillcott<sup>5</sup>, A. Kaan<sup>6</sup>, A. Loo<sup>7</sup>, B. Todd<sup>8</sup>, A. Klemme<sup>9</sup>, W. Piccione<sup>1</sup>, M. Costanzo<sup>1</sup>, <sup>1</sup>Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL; <sup>2</sup>St. Luke's Medical Center, Milwaukee, WI; <sup>3</sup>University of Minnesota, Minneapolis, MI; <sup>4</sup>University of Alabama, Birmingham, AL; <sup>5</sup>Sharp Memorial Hospital, San Diego, CA; <sup>6</sup>St. Vincent's Hospital, Sydney, Australia; <sup>7</sup>University of Pennsylvania, Philadelphia, PA; <sup>8</sup>Temple University, Philadelphia, PA; <sup>9</sup>Fairfax Hospital, Falls Church, VA

11:00 am **(160) WITHDRAWN**

11:15 am **(161) Health-Promoting Lifestyle and Quality of Life in Long-Term Cardiac Transplant Recipients**  
J.J. Salyer<sup>1</sup>, M.P. Flattery<sup>2</sup>, P.L. Joyner<sup>3</sup>; <sup>1</sup>Virginia Commonwealth University School of Nursing, Richmond, VA; <sup>2</sup>Medical College of Virginia Hospitals & Physicians of Virginia Commonwealth University Health Systems, Richmond, VA; <sup>3</sup>McGuire Veterans Administration Medical Center, Richmond, VA

11:30 am **(162) Heart Transplantation in the Older Recipient: Has the Time Come to Reconsider our Selection Policies?**  
K. Hoercher, P.M. Mccarthy, J. Young, N.G. Smedira, R.C. Starling, M.K. Banbury, Cleveland Clinic Foundation, Cleveland, OH

11:45 am **(163) Functional Status and Medical Complications During the First Year Post Lung Transplantation (LTx)**  
D.M. Lanuza, C.A. Lefaiver, M.A. Mccabe, G.A. Farcas, S.M. Bhorade, E.R. Garrity, Jr., Loyola University of Chicago, Maywood, IL

**Noon-12:45 pm**

Box Lunch Pick-up (Exhibit Hall C)

**12:15 pm-1:30 pm**

**Mid-Day Workshop 4: Transplant Nursing: Is That MY Job?!** (Ballroom A)

**Moderators:** Annemarie Kaan, RN and Connie White-Williams, MSN

**Management of VADs: Transitioning from Inpatient to Outpatient**

Tiffany Buda, BSN, RN, Cleveland Clinic Foundation, Cleveland, OH

**Risk Management Issues in Transplantation**

Linda Ohler, MSN, RN, National Institutes of Health, Bethesda, MD

**Debate: Listing Cognitively and Psychologically Challenged Patients for Transplantation: Pros and Cons**

Linda Wright, MSW, CSW, Toronto General Hospital, Toronto, Canada

Catherine M. Murks, MS, RN, University of Chicago, Chicago, IL

**12:15 pm-1:45 pm**

**Mid-Day Workshop 5: Core Curriculum: Immunosuppressive Agents: Insights into Dosing and Interactions** (Ballroom B/C)

Kathleen Lake, PharmD, BCPS, FCCP, University of Michigan Medical Center, Ann Arbor, MI

Gilbert J. Burckart, MD, FCP, FCCP, University of Pittsburgh, Pittsburgh, PA

**12:15 pm-1:45 pm**

**Mid-Day Workshop 6: Neoplasia in Organ Transplantation: What's Growing in This Patient?** (Hall A)

**Moderator:** Gerald J. Berry, MD

Gerald J. Berry, MD, Stanford University, Palo Alto, CA

Sharon Hunt, MD, Stanford University, Palo Alto CA

Joseph M. Connors, MD, University of British Columbia, Vancouver, Canada

**12:15 pm-1:45 pm**

**Mini Oral Poster Presentation Session 2** (Rooms 8 & 15)

**Moderators:** John V. Conte, MD and Paul A. Corris, MD

12:15 pm **(164) Assessment of Coronary Microcirculation in Cardiac Allografts. A Comparison of Intracoronary Physiology, Intravascular Ultrasound and Histological Morphometry**

J. Escaned<sup>1</sup>, J. Segovia<sup>2</sup>, A. Flores<sup>1</sup>, P. Aragoncillo<sup>1</sup>, C. Salas<sup>2</sup>, F. Alfonso<sup>1</sup>, M. López<sup>1</sup>, A. Garcia-Touchard<sup>1</sup>, A. Fernandez-Ortiz<sup>1</sup>, R. Hernandez<sup>1</sup>, C. Bañuelos<sup>1</sup>, M. Sabate<sup>1</sup>, L. Alonso-Pulpon<sup>1</sup>, C. Macaya<sup>1</sup>, <sup>1</sup>Hospital Clinico San Carlos, Madrid, Spain; <sup>2</sup>Hospital Puerta de Hierro, Madrid, Spain

12:21 pm **(165) Panel Reactive Antibody Screening Practices Prior to Heart Transplantation**

A.S. Betkowski, R. Graff, J.J. Chen, P.J. Hauptman, St. Louis University Health Sciences, St. Louis, MO

12:27 pm **(166) Correlation Between the Glomerular Filtration Rate (GFR), Serum Creatinine (Scr), Creatinine Clearance (CrCl) and the Calculated Creatinine Clearance (Calc CrCl) in Heart Transplant (HTx) Patients (pts)**

M. Cantarovich, E. Cyr, R. Chartier, N. Giannetti, R. Cecere, McGill University Health Center, Montreal, Canada

**12:33 pm (167) Even Slightly Impaired Kidney Function (Creatinine>1.79 mmol/l) one Year After Cardiac Transplantation has a Negative Impact on Long Term Survival**

A. Zuckermann, M. Ploner, M. Czerny, K. Uenal, T. Birsan, E. Wolner, G. Laufer, M. Grimm, University of Vienna, Vienna, Austria

**12:39 pm (168) Procalcitonin: A Donor-Specific Predictor of Early Graft Failure and Early Graft Failure Mortality After Heart Transplantation**

F.D. Wagner, B. Jonitz, E. Potapov, N. Qedra, K. Wegscheider, E. Weinmann, M. Loebe, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany

**12:45 pm (169) Influence of Graft Ischemia Time on Outcomes Following Lung Transplantation**

S.M. Fiser, I.L. Kron, S.M. Long, A.K. Kaza, J.A. Kern, C.G. Tribble, University of Virginia, Charlottesville, VA

**12:51 pm (170) Extended Lung Preservation With UW Solution Does Not Adversely Affect Graft Outcome**

D.S. Woolley, L.D. Devito-Haynes, S. Ulschmid, G. Levenson, D.L. Welter, A. Hoffmann, R.D. Cornwell, W.J. Burlingham, K.C. Meyer, R.B. Love, University of Wisconsin, Madison, WI

**12:57 pm (171) The Use of ABO Compatible Non-Identical Organs for Cardiac Transplantation: Are We Treating Potential Recipients With Blood Group O Fairly?**

H. Rexius, U. Nyström, U. Lorentzon, F. Nilsson, A. Jeppsson, Sahlgrenska University Hospital, Gothenburg, Sweden

**1:03 pm (172) Utility of Sublingual Tacrolimus in Cystic Fibrosis Patients After Lung Transplantation**

D. Reams, J. Rea, D. Davis, S. Palmer, Duke University, Durham, NC

**1:09 pm (173) A Multicenter Study to Assess Outcome Following a Switch in the Primary Immunosuppressant From Cyclosporin (CyA) to Tacrolimus (Tac) in Lung Recipients**

W. Klepetko<sup>1</sup>, M. Estenne<sup>2</sup>, A. Glanville<sup>3</sup>, G. Verleden<sup>4</sup>, J.D. Aubert<sup>5</sup>, K. Sarahrudi<sup>1</sup>, M. Gerbase<sup>6</sup>, S. Hirt<sup>7</sup>, H. Reichenspurner<sup>8</sup>, M. Ploner<sup>1</sup>,  
<sup>1</sup>University of Vienna, Vienna, Austria; <sup>2</sup>Hospital Erasme, Brussels, Belgium; <sup>3</sup>St. Vincent's Hospital, Sydney, Australia; <sup>4</sup>University of Ziekenhuizen, Leuven, Belgium; <sup>5</sup>University of Lausanne, Lausanne, Switzerland; <sup>6</sup>University of Geneva, Geneva, Switzerland; <sup>7</sup>University of Kiel, Kiel, Germany; <sup>8</sup>University of Grosshadern, Munich, Germany

**1:15 pm (174) Comparison of Total Lymphoid Irradiation (TLI) Versus Tacrolimus for the Treatment of Obliterative Bronchiolitis (OB) in Lung Transplants**

A. Melville, J. Wardle, G. Parry, P. Corris, J. Dark, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**1:21 pm (175) Exhaled NO (eNO) After Lung Transplantation (LTx): A Prospective Study**

G. Verleden, B. Buyse, M. Delcroix, L. Dupont, D. Van Raemdonck, J. Vanhaecke, University Hospital Gasthuisberg, Leuven, Belgium

**1:27 pm (176) Hospital Transfer of Patients for LVAD Bridge to Transplant: Is Timing Really Critical to Success?**

K. Hoercher, P.M. McCarthy, N. Smedira, M.K. Banbury, R.C. Starling, T.M. Buda, M. Goormastic, S.R. Roberts, J. Young, Cleveland Clinic Foundation, Cleveland, OH

**1:33 pm (177) Timing of VAD Bridging Critical for Outcome of Adult Heart Transplantation**

G. Tenderich, A. Dagge, B. Schulze, U. Schulz, L. Arusoglu, A. El Banayosy, L. Hornik, S. Wlost, K. Minami, R. Koerfer, Heart Center North Rhine-Westphalia, Ruhr-University of Bochum, Bad Oeynhausen, Germany

**1:39 pm (178) Hemodynamic Exercise Testing Reveals a low Incidence of Myocardial Recovery in LVAD Patients**

A. El-Banayosy, L. Arusoglu, L. Kizner, O. Fey, P. Sarnowski, M. Morshuis, H. Milting, H. Koertke, R. Koerfer, Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany

**2:00pm - 3:30pm**

**CONCURRENT SESSION 13**

**Mechanical and Circulatory Support 2: Biological Interactions of Mechanical Ventricular Assist Devices (Hall A)**

**Moderators:** Nicholas G. Smedira, MD and Christoph Schmid, MD

**2:00 pm (179) Altered Expression of Tyrosine Kinase Receptors Her2/Neu and gp130 Following Left Ventricular Assist Device (LVAD) Placement in Patients With Heart Failure**

I.P. Uray<sup>1</sup>, J.H. Connelly<sup>2</sup>, O. Frazier<sup>3</sup>, H. Taegtmeier<sup>1</sup>, P.J. Davies<sup>4</sup>; <sup>1</sup>University of Texas at Houston Medical School, Houston, TX; <sup>2</sup>St.Luke's Hospital, Houston, TX; <sup>3</sup>Texas Heart Institute, Houston, TX; <sup>4</sup>University of Texas Health Science Center, Houston, TX

**2:15 pm (180) Mechanical Unloading Causes Recovery of Calcium Cycling in the Failing Human Heart**

M.L. Ogletree-Hughes, N.G. Smedira, P.M. McCarthy, C.S. Moravec, Cleveland Clinic Foundation, Cleveland, OH

**2:30 pm (181) Evolution and Significance of HLA Allosensitization During Ventricular Assist Device Support**

G.S. Kumpati, D.J. Cook, E.H. Blackstone, J. White, A. Abdo, J.B. Young, R.C. Starling, N.G. Smedira, P.M. McCarthy, Cleveland Clinic Foundation, Cleveland, OH

**2:45 pm (182) LVAD Treated Heart Recipients Do Not Have Deleterious HLA Antibody**

R.H. Kerman<sup>1</sup>, B. Radovancevic<sup>2</sup>, P. Przybylowski<sup>2</sup>, O.H. Frazier<sup>2</sup>, C. Thomas<sup>2</sup>, B.D. Kahan<sup>1</sup>, <sup>1</sup>University of Texas Medical School, Houston, TX; <sup>2</sup>Texas Heart Institute, Houston, TX

**3:00 pm (183) Mechanical Unloading Decreases the Expression of Beta-Tubulin in the Failing Human Heart**

L.A. Aquila-Pastir, P.M. McCarthy, N.G. Smedira, C.S. Moravec, Cleveland Clinic Foundation, Cleveland, OH

**3:15 pm (184) Allosensitization Following Left Ventricular Assist Device (LVAD) Implantation is Dependent on CD40-CD40 Ligand Interactions**

M. Schuster, A.A. Kocher, R. John, E. Kukuy, N. Edwards, M. Oz, S. Itescu, Columbia University, New York, NY

**CONCURRENT SESSION 14**

**2:00 pm - 3:30 pm**

**Clinical Heart Transplantation 3: Graft Failure and Acute Rejection: What's New? (Ballroom A)**

**Moderators:** Maria Rosa Costanzo, MD and Nicholas R. Banner, FRCP

**2:00 pm (185) Determinants of Early Graft Failure Following Cardiac Transplantation, A 10-Year, Multi-Institutional, Multivariable Analysis**

J.B. Young, P.J. Hauptman, D.C. Naftel, G. Ewald, K. Aaronson, G.W. Dec, D.O. Taylor, R. Higgins, L. Platt, J. Kirklin, CTRD at UAB, Birmingham, AL

**2:15 pm (186) Older Recipient Age is Associated With Reduced Alloreactivity and Graft Rejection After Cardiac Transplantation**

R. John, K. Lietz, M. Schuster, D. Mancini, Y. Naka, M. Oz, N. Edwards, S. Itescu, Columbia University, New York, NY

**2:30 pm (187) Wall Motion Assessment by Tissue Doppler Imaging After Heart Transplantation: Timing of Endomyocardial Biopsies and Facilitation of Therapeutic Decisions During Acute Cardiac Rejection**

M. Dandel, M. Hummel, J. Müller, R. Meyer, R. Ewert, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany

**2:45 pm (188) Intravenous Immunoglobulin Therapy in Highly Sensitized Cardiac Allograft Recipients Facilitates Transplantation Across Donor Specific IgG Positive Cross Matches**

R. John, K. Lietz, E. Burke, M. Schuster, E. Yen, Y. Naka, D. Mancini, N. Edwards, M. Oz, S. Itescu, Columbia University, New York, NY

**3:00 pm (189) The Effect of Interleukin-6 Gene Polymorphisms on the Outcome of Cardiac Transplantation**

H. Newell<sup>1</sup>, J. Smith<sup>1</sup>, A. Pomerance<sup>1</sup>, M. Yacoub<sup>2</sup>, M. Rose<sup>2</sup>, <sup>1</sup>Harefield Hospital, Harefield, United Kingdom; <sup>2</sup>Imperial College of Science, Technology & Medicine, University of London, London, United Kingdom

**3:15 pm (190) Computerized Heart Allograft Recipient Monitoring (CHARM) - A Multicenter Study**

B. Grasser<sup>1</sup>, F. Iberer<sup>1</sup>, G. Schreier<sup>2</sup>, S. Schaffellner<sup>1</sup>, D. Kniepeiss<sup>1</sup>, P. Kastner<sup>2</sup>, R. Kleinert<sup>3</sup>, A. Wasler<sup>1</sup>, M. Grimm<sup>4</sup>, A. Zuckermann<sup>5</sup>, W. Rödiger<sup>6</sup>, H. Naegele<sup>6</sup>, H. Demoulin<sup>7</sup>, V. Mahaux<sup>7</sup>, K. Tscheliessnigg<sup>1</sup>; <sup>1</sup>University of Graz, Graz, Austria; <sup>2</sup>Technical University of Graz, Graz, Austria; <sup>3</sup>Karl-Franzens-University Graz, Graz, Austria; <sup>4</sup>Universitätsklinik AKH Wien, Vienna, Austria; <sup>5</sup>University of Vienna, Vienna, Austria; <sup>6</sup>Universitätsklinikum Eppendorf, Hamburg, Germany; <sup>7</sup>Centre Hospitalier Universitaire de Liege, Liege, Belgium

**CONCURRENT SESSION 15**

**2:00PM - 3:30PM**

**Xenotransplantation: Barriers to Success (Ballroom B/C)**

**Moderators:** Richard N. Pierson, III, MD, and Duane Davis, MD

**2:00 pm (191) Total Depletion and Suppression of Natural and Induced Anti-Pig Antibodies in Baboons**

K. Teranishi<sup>1</sup>, B. Gollackner<sup>1</sup>, L. Buhler<sup>1</sup>, C. Knosalla<sup>1</sup>, D.H. Sachs<sup>2</sup>, M. Awwad<sup>3</sup>, D.K. Cooper<sup>1</sup>, <sup>1</sup>Transplantation Biology Research Center, Boston, MA; <sup>2</sup>Massachusetts General Hospital, Charlestown, MA; <sup>3</sup>Biotransplant Inc., Charlestown, MA

**2:15 pm (192) Low Expression of Ecto-5'-Nucleotidase in the Pig Heart - A Potential Barrier to Xenotransplantation**

R. Smolenski<sup>1</sup>, Z. Kochan<sup>2</sup>, J. Karbowska<sup>2</sup>, E. Slominska<sup>2</sup>, M. Forni<sup>3</sup>, K. Kalsi<sup>1</sup>, M.L. Bacci<sup>3</sup>, M. Lavitrano<sup>4</sup>, M.H. Yacoub<sup>5</sup>, <sup>1</sup>Imperial College School of Medicine, Harefield, United Kingdom; <sup>2</sup>Medical University Gdansk, Gdansk, Poland; <sup>3</sup>University of Bologna, Bologna, Italy; <sup>4</sup>Università di Roma "La Sapienza", Rome, Italy; <sup>5</sup>Imperial College of Science, Technology and Medicine, University of London, London, United Kingdom

**2:30 pm (193) The TCR Repertoire of Proliferating T Cells is Restricted by Immunodominant Antigens in the Direct Human Anti-Pig Pathway**

S. Popma, W.Y. Szeto, A.M. Krasinskas, D. Kreisel, A.S. Krupnick, J.S. Moore, B. Rosengard, University of Pennsylvania, Philadelphia, PA

**2:45 pm (194) Human T Cells Express CD86 and Acquire APC Function After Stimulation With Human or Porcine APC**

S.H. Popma, W.Y. Szeto, J.S. Moore, A.S. Krupnick, D. Kreisel, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

**3:00 pm (195) Systemic Vasculitis Complicating Pig to Primate Xenotransplantation**

M.J. Goddard, C. Atkinson, J. Horsley, J.J. Dunning, J. Wallwork, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**3:15 pm (196) Histopathology of Rejection in the Pig-to-Primate Cardiac Xenograft Model**

M.J. Goddard, J.J. Dunning, C. Atkinson, J. Horsley, G. Pino-Chavez, J. Wallwork, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**3:30 pm-4:00 pm**

Coffee Break (Exhibit Hall C)

**3:30 PM-6:30 PM**

Exhibits Open (Exhibit Hall C)

**CONCURRENT SESSION 16**

**4:00 pm - 5:30 pm**

**Alternatives to Transplantation (Hall A)**



**Moderators:** Hermann Reichenspurner, MD, PhD and Francis D. Pagani, MD, PhD

**4:00 pm (197) Cardiac Resynchronisation Therapy for Advanced Heart Failure**

F. Oliva<sup>1</sup>, M. Frigerio<sup>1</sup>, M. Lunati<sup>1</sup>, F.M. Turazza<sup>1</sup>, G. Cattafi<sup>1</sup>, M. Paolucci<sup>1</sup>, A. Garascia<sup>1</sup>, M. Garbellini<sup>1</sup>, G. Magenta<sup>1</sup>, I. Vicini<sup>2</sup>, E. Vitali<sup>1</sup>, G.B. Perego<sup>3</sup>, <sup>1</sup>"A. De Gasperis" Cardiology and Cardiac Surgery Dept., Milan, Italy; <sup>2</sup>Medtronic Italia, Italy; <sup>3</sup>Istituto S. Luca, Milan, Italy

**4:15 pm (198) Efficacy Trends of the Acorn Cardiac Support Device in Patients With Heart Failure: A One Year Follow-up**

H.N. Sabbah<sup>1</sup>, F.X. Kleber<sup>2</sup>, W. Konertz<sup>3</sup>, <sup>1</sup>Henry Ford Health System, Detroit, MI; <sup>2</sup>Unfallkrankenhaus, Berlin, Germany; <sup>3</sup>Charité, Berlin, Germany

**4:30 pm (199) Myosplint® Implantation and Ventricular Shape Change in Patients With Dilative Cardiomyopathy- First Clinical Experience**

S. Schenk, H. Reichenspurner, J.G. Groetzner, D.H. Boehm, J. Schirmer, W.V. Scheidt, B. Reichart, Klinikum Grosshadern, LMU Munich, Munich, Germany

**4:45 pm (200) Determinants of Poor Long-Term Survival After Partial Left Ventriculectomy in Patients With Dilated Cardiomyopathy**

L.P. Moreira, N.A. Stolf, M.L. Higuchi, F. Bacal, E.A. Bocchi, A. Benício, S.A. Oliveira, Heart Institute (Incor), University of São Paulo Medical School, São Paulo, Brazil

**5:00 pm (201) Surgical Management of Severe Emphysema in Australia: Lung Transplant and Lung Volume Reduction Surgery**

P.E. Munro, M. Bailey, D.S. Esmore, T.J. Williams, J.A. Smith, G. Snell, The Alfred Hospital, Prahan, Australia

**5:15 pm (202) Surgical Therapy for Chronic Thromboembolic Pulmonary Hypertension: Criteria for Choosing Lung Transplant vs Thromboendarterectomy**

A.M. D'armini, B. Cattadori, C. Monterosso, V. Emmi, F. Piovella, M. Vigano, San Matteo Hospital, University of Pavia, Pavia, Italy

**CONCURRENT SESSION 17**

**4:00 pm - 5:30 pm**

**Basic Science and Immunobiology 3: Coronary Artery Vasculopathy and Apoptosis (Ballroom A)**

**Moderators:** Thomas D. Wekerle, MD and Gregory M. Hirsch, MD

**4:00 pm (203) Fas-Fas Ligand Death Pathway Does not Contribute to CTL-Mediated Apoptosis of Mouse Vascular Endothelium**

A.S. Krupnick, D. Kreisel, W.Y. Szeto, S.H. Popma, A.M. Krasinskas, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

**4:15 pm (204) Depletion of Recipient CD8+ T Cells Does not Alter the Development of Cardiac Allograft Vasculopathy**

W.Y. Szeto, A.M. Krasinskas, D. Kreisel, A.S. Krupnick, S.H. Popma, B.R. Rosengard, University of Pennsylvania, Philadelphia, PA

**4:30 pm (205) Upregulation of PAI-1 is Mediated Through TGF  $\beta$  /Smad Pathway in Transplant Arteriopathy**

C. Dong<sup>1</sup>, S. Zhu<sup>1</sup>, W. Yoon<sup>1</sup>, T. Wang<sup>1</sup>, R.J. Alvarez<sup>2</sup>, P.J. Goldschmidt-Clermont<sup>1</sup>; <sup>1</sup>Duke University Medical Center, Durham, NC; <sup>2</sup>The Ohio State University, Columbus, OH

**4:45 pm (206) Anti-CD25 Therapy Affects the Death Signals of Activated T-Cells After Clinical Heart Transplantation**

C.C. Baan, A.H. Balk, W.M. Mol, I.C. Van Riemsdijk, P. De Kuiper, T. Van Gelder, P.M. Vantrimpont, A.P. Maat, W. Weimar, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands

**5:00 pm (207) Nitric Oxide Regulates the Apoptotic Pathway in Explanted Failing Human Hearts**

S. Mital<sup>1</sup>, L.J. Addonizio<sup>1</sup>, R.J. Mosca<sup>1</sup>, J.M. Quaegebeur<sup>1</sup>, M.C. Oz<sup>1</sup>, T.H. Hintze<sup>2</sup>, <sup>1</sup>Columbia University, College of Physicians and Surgeons, New York, NY; <sup>2</sup>New York Medical College, Valhalla, NY

**5:15 pm (208) Interleukin-10 Gene Targeting Induced Apoptosis of Alloreactive T Cell Via Fas/FasL Pathway**

K. Oshima, H. Laks, G. Cui, T. Tung, B.M. Sacks, A.A. Kruse, L. Sen, UCLA School of Medicine, Los Angeles, CA

**CONCURRENT SESSION 18**

**4:00 pm - 5:30 pm**

**Pediatrics 1: Long Term Outcome of Pediatric Transplant Recipients (Ballroom B/C)**

**Moderators:** Robert E. Shaddy, MD and Elfriede Pahl, MD

**4:00 pm (209) Pediatric Lung Transplantation and CMV Pneumonitis: A Ten Year Experience**

M. De La Morena<sup>1</sup>, S. Sweet<sup>1</sup>, F. White<sup>1</sup>, E. Mendeloff<sup>1</sup>, G. McBride<sup>2</sup>, C. Huddleston<sup>1</sup>, S. Shapiro<sup>1</sup>, M. Schootman<sup>1</sup>, <sup>1</sup>Washington University, St. Louis, MO; <sup>2</sup>St. Louis Children's Hospital, St. Louis, MO

**4:15 pm (210) Lung Transplantation in Children Following Treatment for Malignancy**

C.B. Huddleston, S. Sweet, S. Shapiro, E.N. Mendeloff, M. De La Morena, Washington University School of Medicine, St. Louis, MO

**4:30 pm (211) Interleukin-2-Receptor Blockade With Daclizumab Decreases the Incidence of Acute Rejection in Pediatric Lung Transplant Recipients**

S.C. Sweet, M.T. De La Morena, S.D. Shapiro, E.N. Mendeloff, C.B. Huddleston, Washington University School of Medicine, Saint Louis, MO

**4:45 pm (212) Clinical Outcome After Starting Carvedilol in Infants and Children With Severe Dilated Cardiomyopathy Candidates for Heart Transplantation**

E. Azeka, J.A. Ramires, M. Ebaid, E. Bocchi, Heart Institute (InCor) University of Sao Paulo Medical School, Sao Paulo, São Paulo, Brazil

**5:00 pm (213) Graft Accommodation in Infant Recipients of ABO-Incompatible Heart Transplants: Donor ABH Antigen Expression in Graft Biopsies**

L.J. West<sup>1</sup>, S.M. Pollock-Barziv<sup>1</sup>, K.J. Lee<sup>1</sup>, A.I. Dipchand<sup>1</sup>, J.G. Coles<sup>1</sup>, P. Ruiz<sup>2</sup>; <sup>1</sup>Hospital for Sick Children/University of Toronto, Toronto, ON, Canada; <sup>2</sup>University of Miami, Miami, FL

**5:15 pm (214) Comparison of Pretransplant Transfusion With or Without Cyclosporin Inhibition on Post Transplant Outcome**

B. Pietra<sup>1</sup>, D.D. Ivy<sup>1</sup>, H.M. Sondheimer<sup>1</sup>, E.M. Shaffer<sup>1</sup>, C. Mashburn<sup>2</sup>, D.W. Ripe<sup>2</sup>, D.J. Gilbert<sup>2</sup>, T.E. Kyle<sup>2</sup>, M.B. Mitchell<sup>1</sup>, D.N. Campbell<sup>1</sup>, M.M. Boucek<sup>1</sup>, <sup>1</sup>University of Colorado Health Sciences Center, Denver, CO; <sup>2</sup>The Childrens' Hospital of Denver, Denver, CO

**5:30 pm - 6:30 pm**

**Moderated Poster Session 2/Wine and Cheese Reception** (Exhibit Hall C)

(Please see page ??? of this program booklet for the list of Poster Session 2 titles and authors - Abstracts 215 - 290)

**6:30 pm - Midnight**

Poster Teardown (Exhibit Hall C)

**6:30 pm - Midnight**

Exhibit Hall Teardown (Exhibit Hall C)

**6:45 pm - 7:45 pm**

Corporate Council Reception (Canada Suite, Pan Pacific Hotel)

**SATURDAY APRIL 28, 2001**

**6:30 am - Noon**

Registration (Convention Centre Lobby)

**6:30 am - 8:00 am**

Morning Coffee/Continental Breakfast (Delegate Concourse)

**6:45 am - 7:45 am**

**Sunrise Symposium 5: Sensational Successes and Fantastic Failures in Lung Transplantation** (Ballroom B/C)

John Dunning, FRCS, Papworth Hospital NHS Trust, Cambridge, United Kingdom

Selim Arcasoy, MD, University of Pittsburgh, Philadelphia, PA

**6:45 am - 7:45 am**

**Sunrise Symposium 6: Sensational Successes and Fantastic Failures in Pediatric Transplantation** (Ballroom A)

John Dark, FRCS, The Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Lori West, MD, PhD, Hospital for Sick Children, Toronto, Canada

**6:45 am - 7:45 am**

**Sunrise Symposium 7: Sensational Successes and Fantastic Failures in Heart Transplantation** (Hall A)

Howard Eisen, MD, Temple University School of Medicine, Philadelphia, PA

Florian Wagner, MD, Herz-und Kreislaufzentrum Dresden, Dresden, Germany

**8:00 AM-10:00 AM**

**PLENARY SESSION (Hall A)**

**Moderators:** Leslie W. Miller, MD and Bruno Reichart, MD

**8:00 am Invited Lecture: The Role of the Endothelium in Rejection**

David Briscoe, MD, Children's Hospital, Boston, MA

**8:30 am Invited Lecture: Pediatric Immunosuppression: Kids Y'nt Us**

Steven A. Webber, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA

**Featured and Caves Candidate Abstracts**

**9:00 am (291) Mouse Vascular Endothelium Activates Alloreactive CD8+ T Lymphocytes in B-7 Dependent Fashion**

D. Kreisel, A.S. Krupnick, W. Szeto, S.H. Popma, A.M. Krasinskas, B. Rosengard; University of Pennsylvania, Philadelphia, PA

**9:15 am (292) European Multicenter Tacrolimus Heart Pilot Study: Three Year Follow-up**

B. Reichart<sup>1</sup>, B. Meiser<sup>1</sup>, M. Viganò<sup>2</sup>, M. Rinaldi<sup>2</sup>, M. Yacoub<sup>3</sup>, N.R. Banner<sup>3</sup>, I. Gandjbakhch<sup>4</sup>, R. Dorent<sup>4</sup>, R. Hetzer<sup>5</sup>, M. Hummel<sup>5</sup>; <sup>1</sup>University of Grosshadern, Munich, Germany; <sup>2</sup>Ospedale Policlinico San Matteo, Pavia, Italy; <sup>3</sup>Harefield Hospital, Harefield, United Kingdom; <sup>4</sup>Hôpital La Pitié-Salpêtrière, Paris, France; <sup>5</sup>German Heart Institute, Berlin, Germany

**9:30 am (293) Monotherapy With Anti-CD40 Ligand Antibody (IDEC 131) for Non-Human Primate Allograft Heart Transplantation**

S. Pfeiffer<sup>1</sup>, G.L. Zorn III<sup>1</sup>, A.M. Azimzadeh<sup>1</sup>, J. Atkinson<sup>1</sup>, R. Newman<sup>2</sup>, R.N. Pierson III<sup>1</sup>; <sup>1</sup>Vanderbilt University, Nashville, TN; <sup>2</sup>IDEC Pharmaceuticals, San Diego, CA

**9:45 am (294) Swan Ganz Catheter Assessment of Donor Hearts - Outcome of Organs With Borderline Haemodynamics**

S.C. Stoica<sup>1</sup>, D.K. Satchithananda<sup>1</sup>, S. Charman<sup>1</sup>, S. Smith<sup>1</sup>, A.N. Redington<sup>2</sup>, S. Tsui<sup>1</sup>, J. Wallwork<sup>1</sup>, S.R. Large<sup>1</sup>; <sup>1</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>2</sup>Great Ormond Street Hospital, London, United Kingdom

**10:00 AM-10:30 AM**

Coffee Break (Delegate Concourse)

**CONCURRENT SESSION 19**

**10:30 AM-NOON**

**(19) Clinical Heart Failure 2: Controversies and Challenges in Treating Advanced Heart Failure (Hall A)**

Moderators: Peter Bergin, MBBS, FRACP and Heather J. Ross, MD

**10:30 am (295) Is Carvedilol Safe and Efficacious in Severe Heart Failure Patients Accepted for Heart Transplantation?**

C.E. Angermann<sup>1</sup>, A. Costard-Jaeckle<sup>2</sup>, M.C. Deng<sup>3</sup>, EFICAT Investigators<sup>4</sup>; <sup>1</sup>Universitaet Muenchen, München, Germany; <sup>2</sup>Christian-Albrechts-Universitaet Kiel, Kiel, Germany; <sup>3</sup>Muenster University, Muenster, Germany; <sup>4</sup>Muenchen, Kiel, and Muenster, Germany

**10:45 am (296) B-type Natriuretic Peptides (BNP and pro-BNP) Predict Longterm Survival in Patients With Advanced Heart Failure Treated With Atenolol**

R. Berger, B. Stanek, B. Frey, B. Sturm, M. Huelsmann, J. Bergler-Klein, R. Pacher; University of Vienna, Vienna, Austria

**11:00 am (297) Are Beta Blockers Effective in African Americans With Systolic Heart Failure?**

R.L. Scott, A. Samal, T. Hamdan, M.H. Park, R. Howard, M.R. Mehra; Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA

**11:15 am (298) Metoprolol Reduces Sympathetic Nerve Hyperactivity in Patients With Heart Failure**

B. Rundqvist<sup>1</sup>, Y. Bergmann-Sverrisdottir<sup>2</sup>, B. Andersson<sup>1</sup>, M. Elam<sup>2</sup>, G. Eisenhofer<sup>3</sup>, F. Waagstein<sup>1</sup>, P. Friberg<sup>1</sup>; <sup>1</sup>Heart and Lung Institute, Goteborg, Sweden; <sup>2</sup>Institute for Clinical Neuroscience, Goteborg, Sweden; <sup>4</sup>National Institutes of Health, Bethesda, Maryland

**11:30 am (299) Survival Benefit of the Implantable Cardioverter/Defibrillator in Patients Listed for Cardiac Transplantation**

S. Sandner, G. Wieselthaler, A. Zuckermann, E. Wolner, M. Grimm; University of Vienna, Vienna, Austria

**11:45 am (300) Beta-Blocker Therapy Reduces Mortality on the Waiting List for Cardiac Transplantation**

M.E. Lanzenberger, S. Sandner, M. Gortlitz, G. Wieselthaler, A. Kocher, S. Taghavhi, M. Ploner, E. Wolner, M. Grimm; General Hospital of Vienna, Vienna, Austria

**10:30 am - Noon**

**(20) Immunosuppression 2: Rats! A Glimpse into the Future of Immunosuppression (Ballroom A)**

Moderators: Howard J. Eisen, MD and Randall E. Morris, MD

**10:30 am (301) CD28/B7-2 Pathway Regulates the Development of Experimental Obliterative Bronchiolitis via Promotion of Th1 Cytokine Expression**

J.M. Tikkanen<sup>1</sup>, K. Lemstrom<sup>2</sup>, V.P. Pulkkinen<sup>2</sup>, P.K. Koskinen<sup>2</sup>; <sup>1</sup>Helsinki University Central Hospital, Helsinki, Finland; <sup>2</sup>Transplantation Laboratory, Helsinki, Finland

**10:45 am (302) Systemic Administration of Recombinant Human Relaxin (rhRlx) Ameliorates the Acute Cyclosporine Nephrotoxicity in Rats**

X. Huang, Z. Cheng, J. Sunga, E. Unemori, K. Zsebo; Connetics Corporation, Palo Alto, CA

**11:00 am (303) Fluvastatin in Combination with RAD Significantly Reduces Transplant Coronary Vasculopathy in Rat Cardiac Allografts**

C.R. Gregory<sup>1</sup>, S. Katznelson<sup>2</sup>, S.M. Griffey<sup>1</sup>, A.E. Kyles<sup>1</sup>, E.R. Berryman<sup>1</sup>; <sup>1</sup>University of California at Davis, Davis, CA; <sup>2</sup>California Pacific Medical Center, San Francisco, CA

**11:15 am (304) MMD Significantly Reduces the Transendothelial Migration of Graft Infiltrating Leucocytes**

M. Richter; Experimental Heart Transplant Group Frankfurt, Parthenstein, Germany

**11:30 am (305) NKH477, a Forskolin Derivative, Exerts an Antiproliferative Effect In Vivo With an Altered Cytokine Profile in Rat Recipients of Orthotopic Lung Allografts**

M. Morikawa, S. Nakashima, K. Komatsu, T. Abe; Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan

**11:45 am (306) 1,25-dihydroxycholecalciferol Reduces Acute Rejection in Rat Lung Allotransplantation**

B. Kubisa<sup>1</sup>, U. Stammberger<sup>1</sup>, A. Gaspert<sup>2</sup>, A.N. Uduehi<sup>1</sup>, C. Redaelli<sup>1</sup>, R.A. Schmid<sup>1</sup>; <sup>1</sup>University Hospital Berne, Berne, Switzerland; <sup>2</sup>University Hospital Zürich, Zürich, Switzerland

**CONCURRENT SESSION 21**

**10:30 am - Noon**

**Donor Management, Preservation, and Organ Distribution 2: Thoracic Organ Donor Evaluation and Management: Clinical (Ballroom B/C)**

Moderators: Bruce R. Rosengard, MD and Ralph A. Schmid, MD

**10:30 am (307) A Randomized Trial of Inhaled Nitric Oxide to Prevent Reperfusion Injury Following Lung Transplantation**

M. Meade<sup>1</sup>, J.T. Granton<sup>1</sup>, A. Matte-Martyn<sup>2</sup>, K. Mcrae<sup>1</sup>, P.M. Cripps<sup>2</sup>, B. Weaver<sup>3</sup>, S.H. Keshavjee<sup>1</sup>, Toronto Lung and Transplant Program<sup>1</sup>; <sup>1</sup>University of Toronto, Toronto, Canada; <sup>2</sup>Toronto General Hospital, Toronto, Canada; <sup>3</sup>McMaster University, Canada

**10:45 am (308) A Positive Donor Gram Stain Does not Predict the Development of Pneumonia, Oxygenation, or Duration of Mechanical Ventilation Following Lung Transplantation**

D. Weill<sup>1</sup>, G.C. Dey<sup>1</sup>, K.R. Young<sup>1</sup>, G.L. Zorn<sup>1</sup>, L.J. Early<sup>1</sup>, R.A. Hicks<sup>2</sup>, J. Kirklin<sup>1</sup>, D.C. McGiffin<sup>1</sup>; <sup>1</sup>University of Alabama-Birmingham, Birmingham, AL; <sup>2</sup>Alabama Organ Center, Birmingham, AL

**11:00 am (309) Pulmonary Vein Gas Analysis for Assessing of Donor Lung Function**

T. Aziz, A. El-Gamel, N. Yonan; Wythenshawe Hospital, Manchester, United Kingdom

**11:15 am (310) Empirical Supportive Therapy in the Hypotensive Donor - Best Guess or Worst Option?**

D.K. Satchithananda<sup>1</sup>, S.N. Stoica<sup>1</sup>, S.N. Smith<sup>1</sup>, M.J. Woods<sup>1</sup>, A.N. Vuylsteke<sup>1</sup>, L.N. Sharples<sup>2</sup>, J.N. Wallwork<sup>1</sup>, J.N. Parameshwar<sup>1</sup>, S.R. Large<sup>1</sup>; <sup>1</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>2</sup>MRC Statistics Unit, Cambridge, United Kingdom

**11:30 am (311) Use of Hearts Transplanted From Donors With Atraumatic Intracranial Bleeds**

D. Marelli, F. Tsai, H. Laks, E. Houston, J. Bresson, L. Friend, D. Gjertson, A. Sykes, A. Ardehali, F. Esmailian, M. Hamilton, G. Fonarow, J. Moriguchi, M. Plunkett, A. Hage, M. Brown, M. Mark, J. Kobashigawa; UCLA, Los Angeles, CA

**11:45 am (312) Evaluation of Extended Donor and Recipient Criteria for Lung Transplantation**

A.F. Pierre, Y. Sekine, M. Hutcheon, S. Keshavjee, T. Waddell; University of Toronto and Toronto General Hospital, Toronto, Ontario, Canada

**Noon – 12:30 pm**

**ANNUAL BUSINESS MEETING** (Members only) (Hall A)

**Noon - 1:00 pm**

Box Lunch Pick-up (Delegate Concourse)

**12:30 PM-2:00 PM**

**ISHLT Scientific Council Meetings** (Rooms 9-12)

**Nursing and Social Sciences** (Room 9)

**Heart Failure & Transplant Medicine** (Room 10)

**Pathology & Basic Science** (Room 11)

**Pulmonary Transplantation** (Room 12)

**Pediatric Transplantation** (Ballroom A)

**Mechanical Circulatory Support** (Ballroom B/C)

**CONCURRENT SESSION 22**

**2:00 pm - 3:30 pm**

**Clinical Heart Transplantation 4: Long-Term Complications** (Hall A)

**Moderators:** Stephan Schueler, MD and James K. Kirklin, MD

**2:00 pm (313) Long-term Renal Function in Heart Transplant Recipients Receiving Tacrolimus (FK506) Therapy**

H. Stempfle, C. Wiescher, B. Meiser, B. Reichart, K. Theisen; University of Munich, Munich, Germany

**2:15 pm (314) WITHDRAWN**

**2:30 pm (315) Immediate Renal Replacement Therapy and Outcome After Cardiac Transplantation – A Multivariate Analysis of Risk Factors**

I. Saeed, C.A. Rogers, A.J. Murday, The UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

**2:45 pm (316) Prevention of Osteoporosis in Cardiac Transplant Recipients**

L.K. Dusek, B.A. Pisani, A.P. Broussard, J. Maly, K. Malinowska, J.A. Mendez, M. Stout, B.K. Foy, G.M. Mullen, J.A. Robinson; Loyola University Health System, Maywood, IL

**3:00 pm (317) Influence of Methylenetetrahydrofolate Reductase Polymorphism on Total Homocysteine Plasma Levels in Heart Transplant Recipients**

L. Potena<sup>1</sup>, F. Grigioni<sup>1</sup>, M.G. Viggiani<sup>2</sup>, G. Magnani<sup>1</sup>, S. Sorbello<sup>1</sup>, L. Bacchi-Reggiani<sup>1</sup>, V. Mantovani<sup>2</sup>, C. Magelli<sup>1</sup>, A. Branzi<sup>1</sup>; <sup>1</sup>Institute of Cardiovascular Diseases, Bologna, Italy; <sup>2</sup>Laboratory of Genetics and Biology, Bologna, Italy

**3:15 pm (318) Posttransplantation Lymphoproliferative Disease in Heart and Heart-Lung Transplant Recipients: Thirty Years Experience at our Hospital**

S. Gao, S. Chaparro, M. Perloth, J. Montoya, T. Hastie, J.L. Miller, P.E. Oyer, J. Schroeder; Stanford University, Stanford, CA

**CONCURRENT SESSION 23**

**2:00 pm - 3:30 pm**

**Lung/Heart-Lung Transplantation 3: Brochial Obliteras Syndrome: Risks and Transbronchial Biopsy** (Ballroom A)

**Moderators:** Marc Estenne, MD and Monique Malouf, FRACP

**2:00 pm (319) Transbronchial Lung Biopsy for Acute Rejection is a Safe Procedure in Lung Transplant Recipients**

P. Hopkins, C. Aboyoum, P. Chhajed, M. Malouf, M. Plit; S. Rainer, A. Glanville, St. Vincent's Hospital, Sydney, Australia

**2:15 pm (320) Diagnostic Yield of Follow-up Transbronchial Lung Biopsies After Acute Rejection in Lung Transplant Recipients**

C.L. Aboyoum, M. Tamm, M. Malouf, S. Rainer, A. Glanville; St Vincent's Hospital, Sydney, Australia

**2:30 PM (321) Success of Lung Transplantation Without Surveillance Bronchoscopy**

V.G. Valentine, D.E. Taylor, G.S. Dhillon, D.M. Fuchs, P.M. Mcfadden, S.P. Kantrow; Ochsner Clinic, New Orleans, LA

**2:45 pm (322) Non-Immune Acute Graft Injury After Lung Transplantation and the Risk of Subsequent Bronchiolitis Obliterans Syndrome (BOS)**

A. Fisher<sup>1</sup>, J.E. Wardle<sup>1</sup>, R. Sipavicius<sup>2</sup>, P. Corris<sup>1</sup>, J. Dark<sup>1</sup>; <sup>1</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom; <sup>2</sup>University Hospital Santariskes, Vilnius, Lithuania

**3:00 pm (323) Hypertonic Saline Challenge Predicts Early Onset Bronchiolitis Obliterans Syndrome Post-Lung Transplantation**

D. Reid<sup>1</sup>, E.H. Walters<sup>1</sup>, D.P. Johns<sup>1</sup>, H. Whitford<sup>1</sup>, C. Ward<sup>2</sup>, S. Khov<sup>1</sup>, P. Liakakos<sup>1</sup>, S. Reid<sup>1</sup>, T.J. Williams<sup>1</sup>, G. Snell<sup>1</sup>; <sup>1</sup>Alfred Hospital, Melbourne, Australia; <sup>2</sup>Medical School, Monash University, Melbourne, Australia

**3:15 pm (324) Bronchoalveolar Lavage (BAL) Neutrophilia in Lung Transplant Recipients (LTR): Infection and Bronchiolitis Obliterans Syndrome (BOS), the Chicken or the Egg?**

H.M. Whitford<sup>1</sup>, B. Orsida<sup>2</sup>, M. Pais<sup>2</sup>, B. Levvey<sup>1</sup>, C. Ward<sup>2</sup>, S. Reid<sup>1</sup>, D. Reid<sup>1</sup>, T.J. Williams<sup>1</sup>, T. Kotsimbos<sup>1</sup>, E.H. Walters<sup>1</sup>, G.I. Snell<sup>1</sup>; <sup>1</sup>Alfred Hospital, Melbourne, Australia; <sup>2</sup>Monash University, Melbourne, Australia

**CONCURRENT SESSION 24**

**2:00 pm - 3:30 pm**

**Pediatrics 2** (Ballroom B/C)

**Moderators:** Daphne T. Hsu, MD and Francesco Parisi, MD

**2:00 pm (325) Death After Cardiac Transplantation in Low Birth Weight Neonates**

R. Chinnock<sup>1</sup>, D. Naftel<sup>2</sup>, T. Singh<sup>3</sup>, C. Canter<sup>4</sup>, B. Pietra<sup>5</sup>, J. Kirklin<sup>2</sup>, W. Morrow<sup>6</sup>, Pediatric Heart Transplant Study Group<sup>7</sup>; <sup>1</sup>Loma Linda Medical Center, Loma Linda, CA; <sup>2</sup>University of Birmingham at Alabama, Birmingham, AL; <sup>3</sup>Children's Hospital of Michigan, Detroit, MI; <sup>4</sup>St. Louis Children's Hospital, St. Louis, MO; <sup>5</sup>The Children's Hospital of Denver, Denver, CO; <sup>6</sup>Arkansas Children's Hospital, Little Rock, AR; <sup>7</sup>Pediatric Heart Transplant Study Group (PHTS)

**2:15 pm (326) Intrathoracic Organ Transplantation in Adults With Congenital Heart Disease**

I. Saeed, C.A. Rogers, A.J. Murday, The UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

**2:30 pm (327) Transplant Coronary Artery Disease in Pediatrics: Favorable Outcome With Medical Therapy**

M.M. Boucek<sup>1</sup>, H.M. Sondheimer<sup>1</sup>, D.D. Ivy<sup>1</sup>, E.M. Shaffer<sup>1</sup>, C. Mashburn<sup>2</sup>, D.W. Ripe<sup>2</sup>, D.J. Gilbert<sup>2</sup>, T.E. Kyle<sup>2</sup>, D.N. Campbell<sup>1</sup>, B. Pietra<sup>1</sup>; <sup>1</sup>University of Colorado Health Sciences Center, Denver, CO; <sup>2</sup>The Children's Hospital of Denver, Denver, CO

**2:45 pm (328) Outcome After Diagnosis of Moderate-Severe Transplant Coronary Artery Disease (TCAD) in Pediatric Heart Transplant Recipients**

R. Hirsch, D.T. Balzer, C.L. Dent, C.B. Huddleston, E.N. Mendeloff, C.E. Canter; Washington University, St. Louis, MO

**3:00 pm (329) Interaction of Volume and Era on Survival of Children Listed for Cardiac Transplantation**

I. Balfour<sup>1</sup>, D. Naftel<sup>2</sup>, J. Fricker<sup>3</sup>, B. Friedman<sup>1</sup>, E. Frazier<sup>4</sup>, R. Shaddy<sup>5</sup>, J. Kirklin<sup>2</sup>, W. Morrow<sup>4</sup>, Pediatric Heart Transplant Study Group<sup>6</sup>; <sup>1</sup>Cardinal Glennon Children's Hospital, St. Louis, MO; <sup>2</sup>University of Birmingham at Alabama, Birmingham, AL; <sup>3</sup>Shands Hospital at the University of Florida, Gainesville, FL; <sup>4</sup>Arkansas Children's Hospital, Little Rock, AR; <sup>5</sup>Primary Children's Medical Center, Salt Lake City, UT; <sup>6</sup>Pediatric Heart Transplant Study Group (PHTS)

**3:15 pm (330) Paediatric Heart Transplantation in the United Kingdom – A Five Year Review of Practice and Results**

I. Saeed, C.A. Rogers, A.J. Murday, The UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

3:30 pm - 4:00 pm

Coffee Break (Delegate Concourse)

**CLOSING PLENARY SESSION (Hall A)**

**4:00 pm - 5:30 pm**

**Moderators:** James B. Young, MD and Robert C. Robbins, MD

**4:00 pm Late Breaking Clinical Trials**

**(331) Effects of the Dual Endothelin Receptor Antagonist Bosentan in patients with Pulmonary Hypertension: A Placebo-Control Study**

Richard N. Channick<sup>1</sup>, D.B. Badesch<sup>2</sup>, V.F. Tapson<sup>3</sup>, G. Simonneau<sup>4</sup>, I. Robbins<sup>5</sup>, A. Frost<sup>6</sup>, S. Roux<sup>7</sup>, M. Rainisio<sup>7</sup>, F. Bodin<sup>7</sup>, L.J. Rubin<sup>1</sup>; <sup>1</sup>University of California, San Diego, CA; <sup>2</sup>University of Colorado, Denver, CO; <sup>3</sup>Duke University, Durham, NC; <sup>4</sup>Hospital Antoine Beclere, Clamart, France; <sup>5</sup>Vanderbilt University, Nashville, TN; <sup>6</sup>Baylor University, Houston, TX, <sup>7</sup>Actelion, France

**4:15 pm Invited Lecture: The Human Genome Project**, Robert Roberts, MD, Baylor College of Medicine, Houston, TX

**4:45 pm Debate: A "Marginal Heart" Transplant is Better than a VAD Bridge**

**Pro:** Valluvan Jevanandam, MD, University of Chicago, Chicago, IL

**Con:** Matthias Loebe, MD, Baylor College of Medicine, Houston, TX

**5:15 pm Debate: Lung Allocation: Medical Urgency, Not Time on List**

**Pro:** Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC

**Con:** Alec Patterson, MD, Washington University School of Medicine, St. Louis, MO

**5:45 pm - 7:30 pm**

**ISHLT Board of Directors Meeting** (Port and Starboard, Pan Pacific Hotel)

**MODERATED POSTER SESSION 1** (Exhibit Hall C)

**Thursday, April 26, 2001**

**5:30 PM - 6:30 PM**

**Moderator: Ari L.J. Harjula, MD**

**(73) Heart-Lung Transplantation for Eisenmenger's Syndrome: Operative Risks and Late Outcomes of 51 Consecutive Cases From a Single Institution**

S.C. Stoica<sup>1</sup>, K. Perreas<sup>1</sup>, L.D. Sharples<sup>1</sup>, D.K. Satchithananda<sup>1</sup>, A.N. Redington<sup>2</sup>, K. McNeil<sup>1</sup>, S.R. Large<sup>1</sup>, J. Wallwork<sup>1</sup>, <sup>1</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>2</sup>Great Ormond Street Hospital, London, United Kingdom

**(74) Intrathoracic Organ Transplantation for Patients With Primary Pulmonary Hypertension**

I. Saeed, C.A. Rogers, A.J. Munday, The UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

**(75) Lung Transplantation for Lymphangioleiomyomatosis**

T.T. Pechet, A.K. Singhal, B.F. Meyers, T.J. Guthrie, R.J. Battafarano, E.P. Trulock, J.D. Cooper, G.A. Patterson, Washington University School of Medicine, St. Louis, MO

**(76) Lung Transplantation in Patients With Scleroderma**

M. Kubo, J. Vensak, J. Dauber, R. Keenan, B. Griffith, K. McCurry, University of Pittsburgh, Pittsburgh, PA

**(77) Accuracy of Currently Utilized Clinical Diagnostic Strategy in Primary Pulmonary Hypertension: Validation Against Pathologic Diagnosis**

J.L. Vensak, S.A. Murali, J.D. Manzetti, Y.A. Samuel, J.H. Dauber, University of Pittsburgh, Pittsburgh, PA

**(78) Mutations in the TGF-beta Type 1 Receptor, ALK1, in Combined Primary Pulmonary Hypertension and Hereditary Haemorrhagic Telangiectasia, Implies Pathway Specificity**

R.C. Trembath, University of Leicester, Leicester, United Kingdom

**(79) Interleukin-8 Release During Ischemia-Reperfusion Correlates With Early Graft Function in Human Lung Transplantation**

M. De Perrot, Y. Sekine, S. Fischer, T.K. Waddell, K. Mcrae, M. Liu, S. Keshavjee, Toronto General Hospital, Toronto, Ontario, Canada

**(80) Influence of Four Different Immunosuppressive Protocols on Acute and Chronic Rejection (BOS) After Lung Transplantation - Experiences in 120 Patients**

H. Treede, H. Reichenspurner, B. Meiser, S. Schenk, F. Kur, H. Furst, C. Vogelmeier, J. Briegel, B. Reichart, Munich University, Munich, Germany

**(81) Features of Bronchoalveolar Lavage (BAL) in Lung Transplant Recipients (LTR) who Later Develop Bronchiolitis Obliterans Syndrome (BOS)**

H.M. Whitford<sup>1</sup>, B. Orsida<sup>1</sup>, M. Pais<sup>2</sup>, B. Levvey<sup>1</sup>, C. Ward<sup>2</sup>, T.J. Williams<sup>1</sup>, T. Kotsimbos<sup>1</sup>, E.H. Walters<sup>1</sup>, G.I. Snell<sup>1</sup>, <sup>1</sup>Alfred Hospital, Melbourne, Australia; <sup>2</sup>Monash University, Melbourne, Australia

**(82) Effect of HLA-DR Mismatch on Lung Transplant Outcome**

R.B. Love<sup>1</sup>, K.C. Meyer<sup>1</sup>, L.D. Devito-Haynes<sup>1</sup>, S. Ulschmid<sup>1</sup>, G.E. Levenson<sup>1</sup>, W. Van Der Bij<sup>2</sup>, W.J. De Boer<sup>2</sup>, B.G. Hepkema<sup>2</sup>, R.D. Cornwell<sup>1</sup>, D.S. Woolley<sup>1</sup>, W.J. Burlingham<sup>1</sup>, <sup>1</sup>University of Wisconsin, Madison, WI; <sup>2</sup>Groningen Lung Transplant Program, Groningen, The Netherlands

**(83) Interventional Bronchoscopy for the Management of Airway Complications Following Lung Transplantation**

P.N. Chhajed, M.A. Malouf, M. Tamm, P. Spratt, A.R. Glanville, St Vincent's Hospital, Sydney, Australia

**(84) Native Lung Volume Reduction Surgery Following Single Lung Transplantation (SLTX) for Emphysema**

J.C. Negri, J. Dunning, L.D. Sharples, K. Mcneil, Papworth Hospital NHS Trust, Cambridge, United Kingdom

**Moderator: Mandeep R. Mehra, MD**

**(85) Outcome of Hepatitis C Positive Donors in Cardiac Transplant Recipients in Triple Drug Immunosuppression (TDI)**

F. Tsai, D. Marelli, H. Laks, J. Bresson, E. Houston, L. Friend, J. Kobashigawa, S. Lackey, R. Camara, UCLA, Los Angeles, CA

**(86) Increased Risk of CMV Infection in Heart Transplant Patients on Mycophenolate Mofetil**

G. Giesler, M. Espejo, B. Kubak, J. Moriguchi, J. Patel, H. Laks, J.A. Kobashigawa, University of California at Los Angeles, Los Angeles, CA

**(87) Long Term Results of Hyperimmunoglobulin CMV-Prophylaxis in 377 Heart Transplant Recipients**

A.A. Kocher<sup>1</sup>, M. Ploner<sup>2</sup>, B. Zwegyick<sup>2</sup>, B. Schlechta<sup>1</sup>, M. Ehrlich<sup>2</sup>, M. Grimm<sup>1</sup>, E. Wolner<sup>1</sup>, G. Laufer<sup>1</sup>, <sup>1</sup>University of Vienna, Vienna, Austria; <sup>2</sup>General Hospital, Vienna, Austria

**(88) Prevalence and Outcome of Hepatitis B Virus (HBV) Infection Following Thoracic Organ Transplantation**

P. Grossi, D. Dalla Gasperina, M. Furione, E. Zerrilli, B. Nocita, G. Spoladore, M. Viganò, L. Minoli, IRCCS Policlinico San Matteo, Pavia, Italy

**(89) Cytomegalovirus Infection Prophylaxis Following Heart Transplantation: Comparison of Two Regimes**

H. Antretter, D. Hofer, H. Hangler, J. Margreiter, C. Larcher, R. Margreiter, G. Laufer, The Leopold-Franzens-University of Innsbruck, Innsbruck, Austria

**(90) Syncope Following Orthotopic Heart Transplantation**

R.M. Sangrigoli, A. Katz, B. Sanchez, H.B. Helfeld, H. Eisen, S. Rothman, Temple University Hospital, Philadelphia, PA

**(91) Morbidity and Mortality Beyond the 10th Year Following Heart Transplant. Data From a Population of 137 Patients**  
L. Sebbag, G. Dureau, P. Boissonnat, J. Gare, J. Obadia, M. Perinetti, R. Loire, Hopital Cardiologique, Lyon Cedex 03, France

**(92) Sudden Death After Heart Transplantation: the Major Mode of Death**

K. Shivkumar, M. Espejo, J. Kobashigawa, M. Watanabe, M. Ikeda, J. Chuang, J. Patel, J. Moriguchi, M. Hamilton, N. Kawata, H. Laks, University of California at Los Angeles, Los Angeles, CA

**(93) Retransplantation of Intrathoracic Organs – Is a Cautious Approach Still Justified?**

I. Saeed, C.A. Rogers, A.J. Murday, The UK Cardiothoracic Transplant Audit, The Royal College of Surgeons of England, London, United Kingdom

**(94) A Multi-Institutional Study of Cardiac Retransplantation: Incidence, Risk Factors for Mortality, and Outcome**

B. Radovancevic, D.C. McGiffin, J.A. Kobashigawa, G.B. Cintron, G.M. Mullen, D.E. Pitts, J. O'Donnell, C. Thomas, R.C. Bourge, D.C. Naftel, CTRD at UAB, Birmingham, AL

**Moderator: Dirk Van Raemdonck, MD, PhD**

**(95) Cardioprotective Effects of ATP-Sensitive Potassium Channel Opener (Cromakalim) in Surgically Induced Cardiac Arrest**

F. Lee<sup>1</sup>, C. Lin<sup>2</sup>, H. Luk<sup>3</sup>, <sup>1</sup>Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ROC; <sup>2</sup>National Defense Medial Center, Taipei, Taiwan, ROC; <sup>3</sup>Taipei Veterans General Hospital, Taipei, Taiwan, ROC

**(96) The Optimal Pressure for Initial Flushout in Heart Procurement With the UW Solution**

J. Mohara<sup>1</sup>, H. Tsutsumi<sup>1</sup>, I. Takeyoshi<sup>1</sup>, M. Tokumine<sup>1</sup>, M. Aizaki<sup>1</sup>, S. Ishikawa<sup>1</sup>, K. Matsumoto<sup>2</sup>, Y. Morishita<sup>1</sup>, <sup>1</sup>Gunma University School of Medicine, Maebashi, Gunma, Japan; <sup>2</sup>Second Hospital of Nippon Medical School, Japan

**(97) Cardiac Allografts With Ischemic Time Over 300 Minutes**

F. Tsai, D. Marelli, H. Laks, E. Houston, A. Sykes, J. Bresson, L. Friend, A. Vellaca, C. Burch, J. Kobashigawa, UCLA, Los Angeles, CA

**(98) Extending Myocardial Preservation With Cyclosporine A Treatment**

T.N. Masters<sup>1</sup>, A.A. Fokin<sup>1</sup>, J. Schaper<sup>2</sup>, L. Pool<sup>2</sup>, G.G. Gong<sup>1</sup>, F. Robicsek<sup>1</sup>, <sup>1</sup>Heineman Medical Research Lab, Carolinas Medical Center, Charlotte, NC; <sup>2</sup>Max Planck Institute, Bad Nauheim, Germany

**(99) Use of Long-Term Preserved Organs in Heart Transplantation: Post-Operative Results and Long Term Follow Up**

L. Sebbag, P. Boissonnat, O. Bastien, M. Chuzel, J. Gare, J. Chassignolle, G. Dureau, J. Obadia, Hopital Cardiologique Louis Pradel, Lyon Cedex, France

**(100) Prospective Randomized Clinical Study of Celsior vs University of Wisconsin in Double Lung Transplant**

A.M. D'Armini, A.M. Grande, M. Rinaldi, C. Goggi, M. Vigano; San Matteo Hospital, University of Pavia, Pavia, Italy

**(101) Controlled Perfusion Decreases Lung Transplant Reperfusion Injury in the Setting of High Flow Reperfusion**

S.M. Fiser, C.G. Tribble, J.A. Kern, S.M. Long, A.K. Kaza, I.L. Kron; University of Virginia Health Sciences Center, Charlottesville, VA

**(102) Effect of Controlled Reperfusion Techniques in Human Lung Transplantation**

C.G. Alvarado, R. Poston, B.G. Hattler, R.J. Keenan, J. Dauber, B. Griffith, K.R. McCurry; University of Pittsburgh, Pittsburgh, PA

**(103) Recipient Intramuscular Gene Transfer of Naked Plasmid TGF- $\beta$ 1 Ameliorates Lung Graft Reperfusion Injury**

N. Daddi<sup>1</sup>, T. Suda<sup>1</sup>, F. D'ovidio<sup>1</sup>, T. Tagawa<sup>1</sup>, N.S. Yew<sup>2</sup>, T. Mohanakumar<sup>1</sup>, G.A. Patterson<sup>1</sup>; <sup>1</sup>Washington University School of Medicine, St. Louis, MO; <sup>2</sup>Genzyme Co., Framingham, MA

**(104) Detection of IL-10 in the Exhaled Breath Condensate, Plasma and Tissue During Ischemia-Reperfusion Injury in Experimental Lung Transplantation**

K. Mcrae, M. De Perrot, S. Fischer, T.K. Waddell, M. Liu, S. Keshavjee; Toronto General Hospital, Toronto, Ontario, Canada

**Moderator: Richard N. Pierson, III, MD**

**(105) Efficiency, Efficacy and Adverse Effects of Adenovirus Versus Liposome-Mediated Ex Vivo Immunosuppressive Cytokine Gene Transfer on the Functional Cardiac Allografts**

L. Sen, Y. Hong, H. Luo, N. Zhou, M. Vargas, H. Laks, G. Cui; UCLA School of Medicine, Los Angeles, CA

**(106) WITHDRAWN**

**(107) Sustained RANTES Production is Necessary for CAV Development**

J.J. Yun, M.P. Fischbein, H. Laks, M. Fishbein, Y. Irie, M. Espejo, J.A. Berliner, A. Ardehali; University of California at Los Angeles, Los Angeles, CA

**(108) The Role of Vitronectin Receptor and Tissue Factor in the Pathogenesis of Transplant Coronary Vasculopathy**

M.H. Yamani, S. Masri, N.B. Ratliff, J.B. Young, R.C. Starling, M. Tuzcu, P. McCarthy, M. Bond; Cleveland Clinic Foundation, Cleveland, OH

**(109) Tc99m MCP-1 Imaging of Chronic Rejection in Rat Cardiac Allografts**

M.H. Kown, F.G. Blankenberg, H.W. Strauss, G.E. Hoyt, R.C. Robbins; Stanford University Medical School, Stanford, CA

**(110) Do Vascular Compartments Differ in the Development of Chronic Rejection?**

M. Richter<sup>1</sup>, H.R. Richter<sup>1</sup>, H.G. Olbrich<sup>1</sup>, F.W. Mohr<sup>2</sup>; <sup>1</sup>Experimental Heart Transplant Group Frankfurt, Parthenstein, Germany; <sup>2</sup>Heart Center Leipzig, Leipzig University, Leipzig, Germany

**(111) Impact of Type 1 Diabetes on Microvascular vs. Macrovascular Involvement With TxCAD: Is There a Difference in Models of the Disease?**

H. Valantine, D. Zhu, P. Wen, S.N. Panchal, X. Dai; Stanford University, School of Medicine, Stanford, CA

**(112) Increased Death Inducing Receptors In Vivo and Activation-Induced T-Cell Death by Anti-Thymocyte Antibody Treatment of Stable Cardiac Transplant Recipients**

H. Ankersmit, B. Moser, I. Teufel, R. Hericis, M. Grimm, G. Boltz-Nitulescu, E. Prof. Wolner; University of Vienna, Vienna, Austria

**(113) WITHDRAWN**

**(114) Immunohistochemical Localization of Oxidized Low-Density Lipoprotein (oxLDL) and Macrophages in Coronary Arteries: Human Heart Allografts Versus Human Native Hearts**

P.C. McDonald, Y. Huang, U. Steinbrecher, M. Loughheed, R. Rahimian, D. Wong, N. Zacher, J. Wilson, B. McManus; St. Paul's Hospital-University of British Columbia, Vancouver, BC, Canada

**Moderator: Aly El-Banayosy, MD**

**(115) Heterotopic Abdominal Heart Transplantation: the Answer to the Donor Shortage?**

D.J. Caparrelli, J.G. Shake, W.A. Baumgartner, J.V. Conte, Jr; The Johns Hopkins Medical Institutions, Baltimore, MD

**(116) A Novel Contractile Artificial Myocardial Tissue - on the way to the Bioartificial Heart**

T. Kofidis, A. Ruhparwar, P. Akhyari, A. Haverich; Hannover Medical School, Hannover, Germany

**(117) Surgical Treatment of Post Infarct Left Ventricular Aneurysm Tachyarrhythmias With Cryoablation and Endoaneurysmorrhaphy**

F. Wellens, P. Geelen, M. Goethals, F. Van Praet, R. De Geest, I. Degrieck, H. Vanermen, P. Brugada; OLV Clinic, Aalst, Belgium

**(118) In Vivo Monitoring of Myoblast Transplantation Into Rat Myocardium**

M.L. Koransky, T.K. Ip, S. Wu, Y. Cao, G. Berry, C. Contag, H. Blau, R. Robbins; Stanford University, Stanford, CA

**(119) Chronic Therapy With the Acorn Cardiac Support Device in Dogs With Chronic Heart Failure: Three and Six Months Hemodynamic, Histologic and Ultrastructural Findings**

H.N. Sabbah, V.G. Sharov, P.A. Chaudhry, G. Suzuki, A. Todor, H. Morita; Henry Ford Health System, Detroit, MI

**(120) Long-term Outcomes of Dynamic Cardiomyoplasty: What we Learned and Challenges for Future Applications**

L.P. Moreira, N.A. Stolf, F. Bacal, E.A. Bocchi, S.A. Oliveira; Heart Institute (Incor), University of São Paulo Medical School, São Paulo, Brazil

**(121) Left Ventricular Assist Device Support for Medically Unresponsive Pulmonary Hypertension From Left Ventricular Failure**

D.Q. Nguyen, S. Ormaza, L.W. Miller, H.B. Bittner, A.G. Rose, R.M. Bolman, S.J. Park; University of Minnesota, Minneapolis, MN

**(122) Aortic Valve Stenosis Induced by Left Ventricular Assist Device (LVAD)**

A.G. Rose<sup>1</sup>, S.J. Park<sup>1</sup>, A.J. Bank<sup>2</sup>, L.W. Miller<sup>1</sup>; <sup>1</sup>University of Minnesota, Minneapolis, MN; <sup>2</sup>United Hospital, St Paul, MN

**(123) Comparison of Postoperative Course of S100 Protein and Neuron-Specific Enolase in Patients After Implantation of Axial and Pulsatile Flow LVADs**

E. Potapov<sup>1</sup>, H. Abdul-Khalig<sup>1</sup>, M. Loebe<sup>1</sup>, A. Koster<sup>1</sup>, R. Sodan<sup>1</sup>, C. Harke<sup>1</sup>, G.P. Noon<sup>2</sup>, R. Hetzer<sup>1</sup>; <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Baylor College of Medicine, Houston, TX

**Moderator: Alan Gass, MD**

**(124) Tacrolimus/Mycophenolate Mofetil vs Cyclosporine/Mycophenolate Mofetil: Comparison of Mycophenolate Acid Trough Levels and Coronary Vasomotor Function**

J. Groetzner, B. Meiser, J. Schirmer, S.S. Schenk, W.V. Scheidt, V. Petrakopulo, M. Weiss, V. Klauss, W. Stempfle, P. Cremer, H. Reichenspurner, B. Reichart; LMU Grosshadern, Munich, Germany

**(125) Tacrolimus Versus Cyclosporine After HTx: Comparison of Long-Term Effects**

J. Schirmer, B. Meiser, A. Kadner, W. Von Scheidt, V. Klauss, P. Cremer, J. Groetzner, S. Schenk, P. Überfuhr, H. Reichenspurner, B. Reichart; University of Munich, Munich, Germany

**(126) Ten Year Experience of FK 506 for Adult Cardiac Transplantation at a Single Institution**

T. Sakai, R.L. Kormos, K.R. Mccurry, J. Ristich, B.G. Hattler, M. Zenati, B.P. Griffith; University of Pittsburgh, Pittsburgh, PA

**(127) The Differential Metabolic Impact of Tacrolimus and Cyclosporine Immunosuppression in Black Heart Transplant Recipients: Hyperlipidemia, Hypertension and Hyperglycemia**

P.A. Uber, M.R. Mehra, N. Vivekananthan, R.L. Scott, M.H. Park; Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA

**(128) Therapeutic Drug Monitoring (TDM) of Prednisolone in Lung Transplantation**

J.M. Morton, B. McWhinney, P.E. Hickman, J.M. Potter; The Prince Charles Hospital, Cherside, Queensland Australia

**(129) Improvement of Chronic Renal Failure After Introduction of Mycophenolate Mofetil and Reduction of Cyclosporine Dose**

G. Rabago<sup>1</sup>, N. Manito<sup>2</sup>, J. Palomo<sup>3</sup>, J.M. Arizón<sup>4</sup>, J. Delgado<sup>5</sup>, L. Almenar<sup>6</sup>, M. Crespo<sup>7</sup>, E. Lage<sup>8</sup>, L. Pulpón<sup>9</sup>; <sup>1</sup>University of Navarra, Pamplona, Spain; <sup>2</sup>Hospital de Bellvitge, Spain; <sup>3</sup>Hospital Gregorio Marañón, Spain; <sup>4</sup>Hospital Reina Sofia, Cordoba, Spain; <sup>5</sup>Hospital 12 de Octubre, Madrid, Spain; <sup>6</sup>Hospital la Fe, Valencia, Spain; <sup>7</sup>Hospital Juan Canalejo, La Coruña, Spain; <sup>8</sup>Hospital Ntra Sra del Rocío, Sevilla, Spain; <sup>9</sup>Clínica Puerta de Hierro, Madrid, Spain



**Moderator: Alain Heroux, MD**

**(130) Introduction of Mycophenolate Mofetil and Cyclosporine Withdrawal in Heart Transplant Patients With Chronic Renal Insufficiency**

M. Garlicki, K. Wierzbicki, Z. Starzyk, P. Rudzinski, T. Wysocka, K. Zmudka, W. Frasik, A. Dziatkowiak; Institute of Cardiology, Jagiellonian University, Krakow, Poland

**(131) Risk Factors and Outcome in Patients With Hemodynamically Unstable Rejection After Heart Transplantation**

J. Jimenez, A. Rosario, A. Morales, W. Tayara, A. Abdo, J. Young, P. McCarthy, R. Starling, D. Cook; Cleveland Clinic Foundation, Cleveland, OH

**(132) Detection and Prediction of Acute Heart Transplant Rejection With the Myocardial T2 Determination Provided by a Black-Blood Magnetic Resonance Imaging Sequence**

P.Y. Marie, J.P. Carteau, J.M. Escanye, O. Claudon, N. David, S. Mattei, N. Hassan, N. Danchin, G. Karcher, A. Bertrand, J.P. Villemot; CHU-Nancy, Vandoeuvre, France

**(133) Effect of Daclizumab Induction Therapy on the Development of Cardiac Transplant Vasculopathy**

D. Mancini, A. Beniaminovitz, N. Edwards, S. Itescu, E. Burke; Columbia University, New York, NY

**(134) Plasma Exchange Before and After Cardiac Transplantation**

A.S. Abdo, D.J. Cook, J.F. McCarthy, E.S. Bishay, G.S. Kumpati, R.C. Starling, J.B. Young, A.P. Koo, N.G. Smedira, P.M. McCarthy; The Cleveland Clinic Foundation, Cleveland, OH

**(135) WITHDRAWN**

**(136) Evaluation of Pre-Transplant Sensitization: A Survey of Tissue Typing Laboratories**

R. Graff, A. Betkowski, P.J. Hauptman; St. Louis University Health Sciences, St. Louis, MO

**(137) Time Course and Determinants of Graft Vascular Remodelling in Heart Transplant Recipients: A Prospective Study**

L. Potena, P. Ortolani, F. Grigioni, G. Magnani, A. Barbieri, C. Marrozzini, E. Falchetti, A. Marzocchi, C. Magelli, A. Branzi; Institute of Cardiovascular Diseases, University of Bologna, Bologna, Italy

**(138) Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Bacteriosclerosis by Chlamydia Pneumoniae?**

T. Wittwer<sup>1</sup>, K. Pethig<sup>2</sup>, B. Heublein<sup>2</sup>, U. Franke<sup>1</sup>, A. Haverich<sup>2</sup>, T. Wahlers<sup>1</sup>; <sup>1</sup>Friedrich-Schiller University Jena, Jena, Germany; <sup>2</sup>Medical School Hannover, Hannover, Germany

**(139) Homocysteine/Coronary Atherosclerosis and Cardiac Transplantation: A Case Control Study**

R.N. Kundur, M. Flattery, M. Hess; Medical College of Virginia, Richmond, VA

**(140) Low Incidence of Graftarteriosclerosis After Cardiac Transplantation - Risk Factor Analysis for Patients With Induction Therapy**

A. Zuckermann, M. Ploner, M. Czerny, K. Uenal, T. Birsan, M. Grimm, G. Laufer, E. Wolner; University of Vienna, Vienna, Austria

**(141) Systemic But Not Cardiac Expression of P-Selection and ICAM-1 Mediate Coronary Microcirculatory Changes in Cardiac Transplant Recipients**

S.M. Wildhirt, M. Weiss, C.H. Sculze, N.E. Conrad, W. Von Scheidt, B. Reichart; Ludwig-Maximilians University, Munich, Germany

**MODERATED POSTER SESSION 2 (Exhibit Hall C)**

**Friday, April 27, 2001**

**5:30 pm - 6:30 pm**

**Moderator: Ramona L. Doyle, MD**

**(215) Coronary Artery Revascularization in Eligible Lung Transplant Recipients**

V.S. Patel, R.H. Messier, S.M. Palmer, R.D. Davis; Duke University Medical Center, Durham, NC

**(216) A Classification System for Severity of Lung Dysfunction After Lung Transplantation: A Predictor of Outcome**

Y. Sekine, T. Waddell, A. Matte-Martyn, A. Pierre, M. Deperrot, S. Fischer, J. Marshall, J. Granton, M. Hutcheon, S. Keshavjee; The Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

**(217) A Cluster of Mycoplasma Hominis Infection in Heart-Lung Transplantation**

P. Hopkins; J. Harkness, M. Horton, A. Keogh, M. Malouf, D. Winlaw; St. Vincent's Hospital, Sydney, Australia

**(218) Hepatitis C Virus Infection After Lung Transplantation: Dim Prognosis**

M.C. Carrenos, U.G. Piedad, L. Maite, V. Andrés, P. Francisca, B. Cesar, M.J. Ferreira Alvarez; Puerta de Hierro, Madrid, Spain

**(219) Impact of Antibiotic-Resistant Pseudomonas on the Survival of Cystic Fibrosis (CF) Patients Following Heart-Lung Transplantation**

S.R. Smith, J. Foweraker, D. Hamilton, J. White, K. McNeil; Papworth Hospital NHS Trust, Cambridge, United Kingdom

**(220) BLTX With Intra- and Postoperatively Prolonged ECMO in Patients With Pulmonary Hypertension: Beneficial Effect on Initial Organ Function**

W. Wisser, G. Marta, Ö. Senbaklavaci, P. Neuhauser, P. Mares, W. Klepetko; University of Vienna, Vienna, Austria

**(221) Intervention Prevents Progression of Osteoporosis in Patients Awaiting Lung Transplantation**

D. Lien, K. Jackson, P. Monkhouse, J. Halenar, J. Mullen, T. Winton, D. Modry, K. Siminoski; University of Alberta, Edmonton, Alberta, Canada

**(222) Prevalence of Sleep Disordered Breathing After Lung Transplantation**

M.A. Malouf, P.N. Chhajed, D. Jankelson, C. Aboyou, R. Grunstein, A.R. Glanville; St. Vincents Hospital, Sydney, Australia

**(223) Pregnancy After Heart-Lung Transplantation**

O. Baron, P. Despins, J.L. Michaud, D. Horeau, M. Treilhaud, A. Haloun; Thoracic Transplantation Unit, Nantes, France

**(224) Impaired Vasodilation During Endothelin-a Receptor Blockade in Lung Transplanted Patients**

M. Silberborn, A. Ambring, H. Scherstén, P. Friberg, A. Jeppsson, F. Nilsson; Sahlgrenska University Hospital, Gothenburg, Sweden

**(225) Single Lung Transplantation for Pulmonary Alveolar Microlithiasis**

K.B. Jackson, D.L. Modry, J. Halenar, J. L'abbe, T.L. Winton, D.C. Lien; University of Alberta Hospital, Edmonton, Alberta, Canada

**Moderator: Adriana Zeevi , PhD**

**(226) Angiotensin II Induces PAI-1 Expression Through Map Kinase-Dependent, but TGFβ and PI3 Kinase-Independent Pathway**

C. Dong<sup>1</sup>, S. Zhu<sup>1</sup>, R.J. Alvarez<sup>2</sup>, P.J. Goldschmidt-Clermont<sup>1</sup>; <sup>1</sup>Duke University Medical Center, Durham, NC; <sup>2</sup>The Ohio State University, Columbus, OH

**(227) HMG-CoA Reductase Inhibitor Cerivastatin Prolonged Rat Cardiac Allograft Survival by Blocking Intercellular Signals**

H. Horimoto, Y. Nakai, K. Nakahara, S. Mieno, S. Sasaki; Osaka Medical College, Takatsuki, Osaka, Japan

**(228) Hepatic Source of C6 Drives Complement-Mediated Cardiac Allograft Injury**

Z. Qian, B. Wasowska, F. Sanfilippo, W.M. Baldwin; Johns Hopkins University School of Medicine, Baltimore, MD

**(229) Apoptosis in Cardiac Allograft Rejection and its Response to Treatment**

S.C. Masri, M.H. Yamani, N.B. Ratliff, A. Almasan, M. Fink, J.B. Young, R.C. Starling, M. Bond; Cleveland Clinic, Cleveland, OH

**(230) The Impact of CD4 And CD8 Transendothelial Migration in the Development of Transplant Arteriosclerosis Following Experimental Cardiac Transplantation**

M.H. Richter<sup>1</sup>, M. Krauss<sup>1</sup>, S. Zahn<sup>1</sup>, H.G. Olbrich<sup>1</sup>, R. Autschbach<sup>2</sup>, F.W. Mohr<sup>2</sup>; <sup>1</sup>Experimental Heart Transplant Group Frankfurt, Parthenstein, Germany; <sup>2</sup>Heart Center Leipzig, University of Leipzig, Leipzig, Germany

**(231) Inducible Expression of Basic Transcription Factor Binding Protein 2 Plays a Potential Role in the Development of the Allograft Vascular Disease**

T. Ogata<sup>1</sup>, R. Nagai<sup>2</sup>, M. Kurabayashi<sup>1</sup>, Y. Hoshino<sup>1</sup>, K. Sekiguchi<sup>1</sup>, K. Kowase<sup>1</sup>, A. Akuzawa<sup>1</sup>, S. Ishikawa<sup>1</sup>, I. Takeyoshi<sup>1</sup>, Y. Morishita<sup>1</sup>, Y. Morishita<sup>1</sup>; <sup>1</sup>Gunma University School of Medicine, Maebashi, Gunma, Japan; <sup>2</sup>Tokyo University School of Medicine, Tokyo, Japan

**(232) CD8+ Lymphocytes Participate in the Development of Chronic Rejection**

M.P. Fischbein, J. Yun, H. Laks, M.C. Fishbein, Y. Irie, C. Wortham, B. Bonavida, A. Ardehali; UCLA, Los Angeles, CA

**(233) Alloregulatory T Cells Producing TGFβ/IL10 can be Generated Ex Vivo**

C. Orosz; Ohio State University, Columbus, OH

**(234) Sudden, Unexpected Death in Cardiac Transplant Recipients: An Autopsy Study**

J.D. Blakey, J. Kobashigawa, H. Laks, M.L. Espejo, M. Fishbein; UCLA Medical Center, Los Angeles, CA

**(235) FK506 vs. Cyclosporin: Pathologic Findings in 1067 Endomyocardial Biopsies**

N.A. Gajjar, J. Kobashigawa, H. Laks, M. Fishbein; UCLA Medical Center, Los Angeles, CA

**(236) Use of en Face Silver Nitrate Staining to Assess Endothelial Gaps and Vascular Permeability in Rat Coronary Artery Transplant Vasculopathy**

J. Dyck, S. Loo, N. Zacher, D. Wong, P.C. McDonald, D.C. Walker, J.E. Wilson, B.M. Memanus; The University of British Columbia - St. Paul's Hospital, Vancouver, B.C., Canada

**Moderator: F. Jay Fricker, MD**

**(237) Safety and Efficacy of Pravastatin in Pediatric Heart Transplant Recipients**

E. Pahl, S.E. Crawford, D.F. Wax, C.L. Backer, C. Mavroudis, S. Gidding; Northwestern University Medical School, Chicago, IL

**(238) Efficacy and Safety of Atorvastatin After Pediatric Cardiac Transplantation**

C. Chin, P. Gamberg, J. Miller, H. Luikart, D. Bernstein; Stanford University, Palo Alto, CA

**(239) Preliminary Experience With IVUS in Pediatric Heart Transplant Recipients**

J. Costello<sup>1</sup>, D. Wax<sup>2</sup>, C.L. Backer<sup>1</sup>, C. Mavroudis<sup>1</sup>, E. Pahl<sup>1</sup>; <sup>1</sup>Northwestern University Medical School, Chicago, IL; <sup>2</sup>Children's Memorial Hospital, Chicago, IL

**(240) Twelve Year Experience With Pediatric Cardiac Replantation**

K.R. Kanter, R.N. Vincent, A.M. Berg, V.K. Tam; Emory University School of Medicine, Atlanta, GA

**(241) Invasive Pneumococcal Infection in Pediatric Heart Transplant Patients**

S. Stovall, K. Ainley, E. Frazier, W. Morrow, G. Schutze; Arkansas Children's Hospital, Little Rock, AR

**(242) Dobutamine/Atropine Stress Echocardiography: Feasibility, Safety and Early Results in Paediatric Heart Transplant Recipients**

A.I. Dipchand, B.W. McCrindle, K. Lee, L.J. West, J.F. Smallhorn; Hospital for Sick Children, Toronto, Ontario, Canada

**(243) Is Renal Function in Paediatric Heart Transplant Recipients Influenced by Late Reduction in Cyclosporine Dosage?**

J.E. Rice, A.T. Shipp, S. Vidmar, R.G. Weintraub; Royal Children's Hospital, Melbourne, Australia

**(244) Specialized, Comprehensive Care Eliminates Racial and Gender Differences in Mortality Between African American and Caucasian Heart Failure Patients**

S.V. Pamboukian, A. Heroux, L. Bartlett, D. Delgado, P. Meyer, E. Winkel, W. Kao, M. Saltzberg, M.R. Costanzo; Rush Presbyterian St. Luke's Medical Center, Chicago, IL

**(245) Humoral and Echo-Doppler Parameters in Predicting the Benefits of Betablockers in Patients With Dilated Cardiomyopathy**

W. Tack, J. Bartunek, E. Van Schuerbeeck, F. Wellens, B. De Bruyne, M. Goethals; Onze Lieve Vrouw Clinic, Aalst, Belgium

**Moderator: Johan Vanhaecke, MD**

**(246) Improvement of Acute Renal Dysfunction (ARD) in Heart Transplant (Tx) Patients (pts) During Calcineurin Inhibitor (CNI) "Holiday" Without Rejection Under Anti-CD25 Monoclonal Antibody (MAB) Coverage**

M. Cantarovich, N. Giannetti, E. Cyr, R. Chartier, R. Cecere; McGill University Health Center, Montreal, Canada

**(247) Prevention of Accelerated Rejection and Prolonged Survival in Sensitized Rats With Cyclophosphamide Therapy**

N. Ma, M. Szabolcs, R. John, A. Weinberg, S. Itescu, N. Edwards; Columbia University, New York, NY

**(248) In Vivo Effect of Sirolimus on T Cells, B Cells and Monocytes in Non-Human Primates**

C. Dambin, T. Birsan, J. Klupp, U. Christians, R. Morris; Stanford University, Stanford, CA

**(249) Cyclosporine Does not Enhance the Development of Chronic Rejection. Experimental Study in a Rat Cardiac Transplant Model**

M. Richter, D. Schramm, H.R. Richter, H.G. Olbrich; Experimental Heart Transplant Group Frankfurt, Parthenstein, Germany

**(250) Membrane Transport of Mycophenolate Mofetil and its Active Metabolite, Mycophenolic Acid in MDCK and MDR1-MDCK Cell Monolayers**

T. Sawamoto<sup>1</sup>, T. Van Gelder<sup>2</sup>, U. Christians<sup>1</sup>, N. Okamura<sup>1</sup>, W. Jacobsen<sup>1</sup>, L. Benet<sup>1</sup>; <sup>1</sup>UCSF, San Francisco, CA; <sup>2</sup>University Hospital Rotterdam, Rotterdam, The Netherlands

**(251) MMF- A New Cornerstone in Immunosuppressive Therapy After Cardiac Transplantation**

M. Richter<sup>1</sup>, H.R. Richter<sup>1</sup>, H.G. Olbrich<sup>1</sup>, R. Autschbach<sup>2</sup>, F.W. Mohr<sup>2</sup>; <sup>1</sup>Experimental Heart Transplant Group Frankfurt, Parthenstein, Germany; <sup>2</sup>Heart Center Leipzig, University of Leipzig, Leipzig, Germany

**(252) Comparative Study of CSA and FK506 Versus Newer Immunosuppressive Drugs MMF and Rapamycin on Coronary Endothelial Function In Vitro**

H. Jeanmart, L.P. Perrault, M. Carrier, R. Cartier, C. Nickner; Montreal Heart Institute, Montreal, Quebec, Canada

**Moderator: John Jarcho, MD**

**(253) The Diminishing Impact of Pretransplant Pulmonary Hypertension on Perioperative Mortality After Cardiac Transplantation**

J.M. Chen, P. Sinha, H.A. Rajasinghe, R. John, D.M. Mancini, H.M. Hauff, N.M. Edwards; Columbia University, New York, NY

**(254) The Value of Exhaled Co-Measurement for Detection of Smoking After Heart Transplantation**

M. Riha<sup>1</sup>, P. Bayer<sup>2</sup>, D. Höfer<sup>1</sup>, E. Groman<sup>2</sup>, M. Kunze<sup>2</sup>, M. Grimm<sup>3</sup>, G. Laufer<sup>1</sup>; <sup>1</sup>University of Innsbruck, Innsbruck, Austria; <sup>2</sup>Institution for Social Medicine, Vienna, Austria; <sup>3</sup>University Vienna, Vienna, Austria

**(255) Statins Improve Long-Term Survival and Reduce Incidence of Hemodynamically Significant Rejection**

I. Stojanovic, B. Radovancevic, C.D. Thomas, I. Gregoric, R. Radovancevic, J.K. Ho, O.H. Frazier; Texas Heart Institute, Houston, TX

**(256) Longer Distance From Transplant Center is not Associated With Decreased Survival in Post Cardiac Transplant Patients**

S. Kushwaha, R.J. Rodeheffer, T. Weiss, J. Jarcho, M. Pritzker, A.L. Smith, K.J. Heilman, B.S. Clemson, B.K. Rayburn, R. Bourge, J. Kirklin; CTRD at UAB, Birmingham, AL

**(257) Monoclonal Gammopathy in Heart Transplantation: Clinical Significance and Risk Factors**

A.L. Caforio, A. Gambino, A. Belloni Fortina, S. Piaserico, E. Scarpa, G. Feltrin, F. Tona, M. Alaibac, G. Amadori, G. Thiene, S. Dalla Volta, A. Peserico, D. Casarotto; Padua University, Padua, Italy

**(258) Ventricular Asynchrony After Heart Transplantation: Prevalence and Clinical Correlates**

S. Potluri, A. Prasad, P.A. Uber, R.L. Scott, M.H. Park, M.R. Mehra; Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA

**(259) Preoperative Amiodarone Increases Risk of Bleeding Complications Following Cardiac Transplantation**

P. Blomberg, D. Denofrio, G. Chen, N.A. Estes, M.S. Link; New England Medical Center, Boston, MA

**(260) Is Outcome After Heart Transplantation Influenced by Ethnicity? A Comparison of African Americans Versus Caucasians**

S.V. Pamboukian, A. Heroux, L. Bartlett, M. Mcleod, P. Meyer, E. Winkel, W. Kao, M. Saltzberg, M.R. Costanzo; Rush Presbyterian St. Luke's Medical Center, Chicago, IL

**(261) Myocardial Ischemic Injury Following Heart Transplantation is Associated With Decreased Risk of Acute Cellular Rejection in the Absence of Humoral Rejection**

M.H. Yamani, D. Cook, R.C. Starling, N.B. Ratliff, J.T. McMahon, A. Abdo, M. Tuzcu, P. McCarthy, J.B. Young; Cleveland Clinic Foundation, Cleveland, OH

**(262) Procalcitonin (PCT) is a new Biological Marker for the Diagnosis of Non-Viral Infections After Transplantation of Intrathoracic Organs**

N. Qedra, F. Wagner, B. Jonitz, M. Loebe, K. Abraham, R. Hetzer; German Heart Institute, Berlin, Germany

**Moderator: Hikaru Matsuda, MD**

**(263) The Internal Cardiac Defibrillator for VT on LVAD Support**

S.R. Roberts, K. Hoercher, P.M. McCarthy, N.G. Smedira, M.K. Banbury, M. Goormastic, R.C. Starling, J. Young; Cleveland Clinic Foundation, Cleveland, OH

**(264) Extracorporeal Membrane Oxygenation for Neonates With Single Ventricle and Parallel Circulations**

C. Pizarro, D.A. Davis, P.J. Kerins, R.C. Raphaely, E.A. Spurrier, W.I. Norwood; Nemours Cardiac Center, Wilmington, DE

**(265) Effect of the Abiocoar Implantable Replacement Heart on Immune System Function**

C.L. Kaufman, N. Melo, L.M. Ryle, K. Stevens, R.D. Dowling; University of Louisville, Louisville, KY

**(266) Native Ventricular Performance After one Year of Left Ventricular Support**

A. El-Banayosy, L. Arusoglu, L. Kizner, O. Fey, P. Sarnowski, M. Morshuis, H. Milting, H. Koertke, R. Koerfer; Heart Center North Rhine-Westphalia, Bad Oeynhausen, Germany

**(267) Improved Myocardial Structure Following LVAD Support: Effect of Unloading on Dystrophin Expression**

S.J. Stetson, A. Perez-Verdia, M. Vatta, N.E. Bowles, J.A. Towbin, G. Torre-Amione; Baylor College of Medicine, Houston, TX

**(268) Nitric Oxide Inhalation Modulates Endothelin-1 and Big Endothelin-1 After Left Ventricular Assist Device Implantation**

F.D. Wagner<sup>1</sup>, S. Buz<sup>1</sup>, C. Knosalla<sup>1</sup>, M. Loebe<sup>1</sup>, R. Hetzer<sup>1</sup>, B. Hoher<sup>2</sup>; <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany; <sup>2</sup>Charite, Berlin, Germany

**(269) LVAD Therapy Improves Utilization of Donor Hearts: Implications for Prolonged Inotropic Therapy**

K. Aaronson, M. Eppinger, S. Wright, F.D. Pagani; University of Michigan, Ann Arbor, MI

**(270) LVAD Blood Stream Infection: Therapeutic Rationale for Transplantation**

R.S. Poston, D.N. Sorce, S. Husain, E.A. Stanford, S. Winowich, S. Kusne, B.P. Griffith, R.L. Kormos; University of Pittsburgh, Pittsburgh, PA

**(271) Changes in the Solid Organ Donor Pool and the Effect on Cardiothoracic Donation?**

F.M. Seeney, M.A. Belger, F.C. Fordham; UK Transplant, Bristol, United Kingdom

**(272) Predictors of Death on the UNOS Lung Transplant Waiting List: Results of a Multivariate Analysis**

T.M. Egan<sup>1</sup>, L.E. Bennett<sup>2</sup>, E.R. Garrity<sup>3</sup>, F.L. Grover<sup>4</sup>, W.S. Ring<sup>5</sup>, R.C. Robbins<sup>6</sup>, E. Trulock<sup>7</sup>, D.E. Wood<sup>8</sup>; <sup>1</sup>University of North Carolina, Chapel Hill, NC; <sup>2</sup>UNOS, Richmond, VA; <sup>3</sup>Loyola University, Maywood, IL; <sup>4</sup>University of Colorado, Boulder, CO; <sup>5</sup>University of Texas Southwestern, Dallas, TX; <sup>6</sup>Stanford University, Stanford, CA; <sup>7</sup>Washington University, St. Louis, MO; <sup>8</sup>University of Washington, Seattle, WA

**(273) WITHDRAWN**

**(274) Systolic Right Ventricular Dysfunction in 'Good' Donor Hearts- A Normal Finding?**

D.K. Satchithananda<sup>1</sup>, S.C. Stoica<sup>1</sup>, P.A. White<sup>2</sup>, S.N. Charman<sup>3</sup>, H.N. Luckraz<sup>1</sup>, P.M. Schofield<sup>1</sup>, J.N. Wallwork<sup>1</sup>, J.N. Parameshwar<sup>1</sup>, A.N. Redington<sup>2</sup>, S.R. Large<sup>1</sup>; <sup>1</sup>Papworth Hospital, Cambridge, United Kingdom; <sup>2</sup>Great Ormond Street Hospital, London, United Kingdom; <sup>3</sup>MRC Statistics Unit, Cambridge, United Kingdom

**Moderator: Mary Amanda Dew, PhD**

**(275) Ratings of Children's Self Perception Before and one Year After Transplantation: Do Children and Their Parents Agree?**

J.C. Wray, R.C. Radley-Smith; Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

**(276) Optimizing Heart Transplant Patient Education: Is Once Enough?**

A. Bordelon, P.A. Uber, D. Dumas-Hicks, M.H. Park, R.L. Scott, M.R. Mehra; Ochsner Cardiomyopathy and Heart Transplant Center, New Orleans, LA

**(277) The Dilemma of Disability After Heart Transplantation**

M. Espejo, J. Kobashigawa, J. Moriguchi, J. Patel, N. Kumar, M. Hamilton, A. Hage, N. Kawata, H. Laks; University of California at Los Angeles, Los Angeles, CA

**(278) Heart Failure (HF): Are Nurses Providing Patients With Optimal Education of Self-Care Principles?**

N.M. Albert<sup>1</sup>, V. Sumodi<sup>2</sup>, S. Wilkinson<sup>3</sup>, L. Vopat<sup>4</sup>, C. Willis<sup>5</sup>, B. Bittel<sup>6</sup>, S. Collier<sup>6</sup>, J.P. Hammel<sup>1</sup>; <sup>1</sup>The Cleveland Clinic Foundation, Cleveland, OH; <sup>2</sup>Hillcrest Hospital, Mayfield Heights, OH; <sup>3</sup>Cleveland Clinic Home Care, Cleveland, OH; <sup>4</sup>Marymount Hospital, OH; <sup>5</sup>Fairview Hospital, OH; <sup>6</sup>Southpointe Hospital, Warrensville Heights, OH

**(279) Pediatric Living Donor Lung Transplantation: Psychosocial Considerations**

M.S. Markovitz<sup>1</sup>, A. Doyle<sup>2</sup>, M.A. Shaner<sup>1</sup>, D. Schuller<sup>2</sup>, S.C. Sweet<sup>2</sup>; <sup>1</sup>St. Louis Children's Hospital, St. Louis, MO; <sup>2</sup>Washington University School of Medicine, St. Louis, MO

**Moderator: Mauro Rinaldi, MD**

**(280) Diabetes Affects Long-Term Survival After Heart Transplantation**

M. Czerny, V. Sahin, A. Zuckermann, D. Zimpfer, J. Kilo, H. Baumer, E. Wolner, M. Grimm; University of Vienna, Vienna, Austria

**(281) Diabetes Related Complications in Patients After Heart Transplantation**

M. Czerny, V. Sahin, A. Zuckermann, D. Zimpfer, J. Kilo, H. Baumer, E. Wolner, M. Grimm; University of Vienna, Vienna, Austria

**(282) Incidence of Erectile Dysfunction and Efficacy of Sildenafil in the Cardiac Transplantation Patient**

F.J. Wren, M.V. Jarowenko, J. Burg, J. Boehmer; Penn State University Milton S Hershey Medical Center, Hershey, PA

**(283) A Randomised Controlled Trial of Antihypertensive Treatment With Valsartan After Heart Transplantation**

N.J. Marcus<sup>1</sup>, J.B. Breen<sup>1</sup>, M.H. Yacoub<sup>2</sup>, N.R. Banner<sup>1</sup>; <sup>1</sup>Harefield Hospital, Harefield, Middlesex, United Kingdom; <sup>2</sup>Imperial College of Science and Technology, London, United Kingdom

**(284) Right Atrial Geometry and Tricuspid Regurgitation After Orthotopic Heart Transplantation: Benefits of a Modified Batrial Surgical Technique**

M. Dandel, M. Hummel, C. Knosalla, M. Loebe, Y. Weng, J. Müller, S. Buz, R. Ewert, R. Hetzer; Deutsches Herzzentrum Berlin, Berlin, Germany

**(285) Optimal Management of Severe Tricuspid Regurgitation in Cardiac Transplant Recipients**

C. Anderson, F. Filsoufi, R.S. Farivar, D.H. Adams; Brigham and Women's Hospital, Boston, MA

**(286) Immunologic Events and Long Term Survival After Combined Heart and Kidney Transplantation : A Twelve-Year Single-Center Experience**

E. Vermes, M. Kirsch, R. Houel, S. Legouvelo, E. Aptecar, C. Benvenuti, P. Lang, C. Abbou, D. Loisançe; Hopital Henri Mondor, Créteil, France

**(287) Reversal of Chronic Cyclosporin Nephrotoxicity After Heart Transplantation**

T. Tedoriya, P.S. Macdonald, A.M. Keogh, M. Wilson, P.M. Spratt; St. Vincent's Hospital, Sydney, Australia

**(288) Outcome of Heart Transplant in Patients With Renal Insufficiency**

F.L. Adajar, C.E. Lawless, K. Malinowska; Loyola University Health System, Maywood, IL

**(289) Pituitary Stimulation in Cardiac Transplant Recipients With Low Free Testosterone Levels**

J. Edwards<sup>1</sup>, L. Straatman<sup>2</sup>, S. Abbey<sup>3</sup>, D. Arab-O'brian<sup>4</sup>, D. Delgado<sup>3</sup>, E. Young<sup>1</sup>, L. Luu<sup>1</sup>, H.J. Ross<sup>1</sup>; <sup>1</sup>University of Toronto, Toronto, Ontario, Canada; <sup>2</sup>St. Paul's Hospital, Vancouver, BC, Canada; <sup>3</sup>Toronto General Hospital, Toronto, Ontario, Canada; <sup>4</sup>St. Joseph's Hospital, Canada

**(290) Hypotensive Reactions Associated With Transfusion of Bedside Leukocyte Reduction Filtered Blood Products in Heart Transplanted Patients**

J. Lavee, Y. Paz; Sheba Medical Center, Tel Hashomer, Israel

## List of Exhibitors

ABIOMED, INC.  
BOOTH #309  
Cherry Hill Dr.  
Danvers, MA 01923  
Phone: 978-777-5410  
Fax: 978-777-1561  
Contact: Dean Landry

The BVS 5000® Bi-Ventricular Support System is used on patients suffering from reversible ventricular dysfunction. A unique dual chamber design provides optimal pulsatile flow to the vital organs, while completely resting the myocardium. The ABIOMED Abiomed™ Implantable Replacement Heart is in an advanced state of development and not available for sale of human use.

ACORN CARDIOVASCULAR, INC.™  
BOOTH #409  
601 Campus Dr.  
St. Paul, MN 55112  
Phone: 651-286-4800  
Fax: 651-286-4848  
Contact: Laura Von Holtum

OUS 2001  
Acorn Cardiovascular, Inc.™, is a privately held medical device manufacturer developing therapies for heart failure. The company's first product is the CorCap Cardiac Support Device™, a promising new therapy for patients with dilated cardiomyopathy. The CorCap is a mesh-like cap for patients with dilated cardiomyopathy. The CorCap is a mesh-like cap that is easily slipped around the heart and adjusted to fit. By supporting the heart and reducing stress-mediated myocardial stretch, the Co4rCap passively works to stabilize or reduce heart size and improve cardiac function. The CorCap is used in conjunction with medical management and is complementary to standard cardiac surgery such as valve repair/replacement or coronary artery bypass grafting. Recently, Acorn obtained CE Mark for the CorCap and is conducting a multi-center clinical trial in the U.S.

ACTELION PHARMACEUTICALS, U.S.  
BOOTH #208  
601 Gateway Blvd, Suite 100  
South San Francisco, CA 94080  
Contact: Terrell Sweat  
Phone: 650-624-6900 Ext. 6910  
Fax: 650-589-1501

Actelion Pharmaceuticals U.S., Inc. is the Sales and Marketing subsidiary of a bio-pharmaceutical company headquartered in Switzerland. Actelion is the global leader in creative science related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. Actelion concentrates on developing and bringing innovative drugs to the patients. Tracleer (bosentan) for chronic heart failure and pulmonary hypertension and tezosenan for acute heart failure, are the two flagship drugs in late stage development.

ARROW, INTERNATIONAL  
BOOTH #408  
Hill and George Avenues  
Reading, PA 19610  
Phone: 610-378-1606  
Fax: 610-478-3184  
Contact: Tami Zook

For tomorrow's technology in cardiac assist, see Arrow's revolutionary LionHeart™ Intra-Aortic Balloon pump, and Ultr 8™ IAB catheter. The Arrow LionHeart™ LVAS, now in IDE clinical trial, is a ventricular assist system that is designed as a destination therapy system and not for bridge to transplant. The Arrow LionHeart™ is electrically driven, totally implantable, and completely transcatheter, with no tethers. The AutoCAT™ will automatically select the proper trigger, set the correct balloon timing, and

adjust the balloon volume. The Ultra 8™ will automatically select the proper trigger, set the correct balloon tiing, and adjust the balloon volume. The Ultra 8™ IAB catheter is the only one that fits through any 8 Fr Sheath and accepts a .025” guide wire.

BIOTEST PHARMA GMBH  
BOOTH #404  
Landsteuerstr. 5  
Dreiech, Germany 63303  
Phone: 49-6103-801-751  
Fax: 49-6103-801-737  
Contact: Georg Ebers

Plasma derived Immunoglobulines

BIOMAX TECHNOLOGIES, INC.  
BOOTH #308  
Suite 300 – 1190 Hornby Street  
Vancouver, British Columbia  
CANADA V5Z 2G3  
Phone: 604-638-2770  
Fax: 604-638-2771  
Contact: Jack Saladow

Biomax is engaged in the development of a device intended to replace the endomyocardial biopsy (EMB) procedure for the diagnosis of rejection in heart transplant patients. The Optical Catheter System (Biomax OCS) is designed to replace the current EMB standard with a rejection monitoring procedure that is less invasive to the patient and gives immediate feedback to the medical team, allowing them to appropriately modify treatment immediately. The Optical Catheter System is not approved for sale of use in the United States or any other jurisdiction at this time. The Company expects clinical trials of the Optical Catheter System to commence in June of 2001.

CARDIOWEST TECHNOLOGIES, INC.  
BOOTH #310  
1501 N. Campbell Ave #4607  
Tucson, AZ 85724  
Phone: 520-694-5200  
Fax: 520-594-2630  
Contact: Richard Smith, MSEE, CCE

The CardioWest C-70 total artificial heart is a pulsatile bi-ventricular device that replaces a patient’s native ventricles and valves, relieving in total the heart’s workload by pumping blood to both the pulmonary and systemic circulation. The system consists of the implantable C-70 TAH, and an external console connected by drivelines. The CardioWest total artificial heart is the only total artificial heart used in a bridge to transplant application in the world. In Europe and Canada it is a commercial product (CE mark, ISO certified). In the United States, it is certified for use by the FDA (DE G920101) at five centers. The clinical study is in the final stage, with PMA expected this year.

CHIRON CORPORATION  
BOOTH #503  
4560 Horton Street, M/S U-544A  
Emeryville, CA 94608  
Phone: 510-923-6710  
Fax: 510-923-3897  
Contact: Leslye McKay

Visit the booth to learn about TOBI® (Tobramycin Solution for Inhalation). TOBI® is specifically formulated for administration by inhalation. When inhaled, tobramycin is concentrated in the airways. TOBI® is indicated for the management of cystic fibrosis patients with P. aeruginosa.

TOBI® is a sterile, clear, slightly yellow, nonpyrogenic, aqueous solution, with the pH and salinity adjusted specifically for administration by a compressed air-driven reusable nebulizer. Each single-use 5mL ampule contains 300mg tobramycin and 11.25 mg sodium chloride in sterile water for injection. The formulation contains no preservatives.

For more information go to [www.abouttobi.com](http://www.abouttobi.com)

**CINCINNATI TRANSPLANT INSTITUTE**

2351 Auburn Avenue  
Cincinnati, OH 45219  
Phone: 513-381-2844  
Fax: 513-381-2235  
Contact: Lynn Fallon

The Cincinnati Transplant Institute is a transplant service company dedicated developing therapeutic and diagnostic solutions to transplant patients, caregivers, and centers, as well as industry and government affairs surrounding transplant. Areas of focus include clinical research, education, laboratory testing, and practice management.

**ELSEVIERE SCIENCE INC.**

BOOTH #511  
655 Avenue of the Americas  
New York, NY 10010  
Phone: 212-633-3733  
Fax: 212-633-3112  
Contact: Julian Sulmonetti

**FUJISAWA HEALTHCARE, INC.**

BOOTH #303  
Three Parkway North  
Deerfield, IL 60015  
Phone: 847-317-8800  
Fax: 847-317-7281  
Contact: Carl Kincaid, Product Director, Immunology

Fujisawa Healthcare, Inc., will have representatives available to discuss Prograf (tacrolimus), indicated for the prophylaxis of organ rejection in patients receiving allogenic liver and kidney transplants.

**MEDICAL INSIGHT RESEARCH**

BOOTH #505  
C/o Putnam Associates, Inc.  
25 Burlington Mall Rd.  
Burlington, MA 01803  
Phone: 781-273-5480  
Fax: 781-273-5484  
Contact: Curtis LeGeyt

We are a market research firm that specializes in the pharmaceutical and biotechnology industries in the U.S. and worldwide. Participants in this year's survey, in which we are assessing trends in immunosuppression, will receive a complimentary gift.

**MEDIMMUNE, INC.**

BOOTH #402  
35 West Watkins Mill Road  
Gaithersburg, MD 20878  
Phone: 301-527-4338  
Fax: 301-57-4203  
Contact: Carol A. Collins, CMP



MedImmune, Inc. is a fully integrated biotechnology company focused on a developing and marketing products that address medical needs in areas such as infectious disease, transplantation medicine, autoimmune disorders and cancer. Headquartered in Gaithersburg, Maryland, MedImmune has manufacturing facilities in Frederick, Maryland and Nijmegen, The Netherlands.

NOVARTIS PHARMACEUTICALS CORPORATION

BOOTH: 203

59 Route 10

East Hanover, NJ 07936

Phone: 973-781-5361

Fax: 973-781-5488

Contact: Gina Edwards

As a leading contributor to the advancement of transplant science and medicine for over 16 years, Novartis Pharmaceuticals Corporation continues to build on the proven clinical success of Neoral cyclosporine, USP (MODIFIED), Simulect (basiliximab) and Sanimmune (cyclosporine, USP). Our focus is to develop meaningful therapeutic advances that improve recipient quality of life and enhance the long-term success of transplantation. In partnership with the transplant community, we have created the broadest pipeline in the field with three compounds in clinical trials and eleven projects in pre-clinical development.

ROCHE

BOOTH: 103

PBC Congresses

Bldg 74 / 4<sup>th</sup> Floor/409

4070 Basel

Switzerland

Phone: 41-61-688-71-26

Fax: 41-61-688-14-09

Contact: Nils Meyer, International Congress Manager

CellCept/Roche

Integral to immunosuppressive regimens for the prevention of rejection in kidney, heart and liver transplants, CellCept also improves long term graft survival and allows reduction of the efficacy limiting toxicities of the other more toxic immunosuppressants in the long term.

As part of Roche's commitment to Transplantation, Roche funds the ROTRF (Roche Organ Transplant Research Foundation), an independent to explore clinical and basic science in transplantation. Roche also has in development, valganciclovir, a new treatment for CMV, a virus that affects some transplant patients. Roche also has a large clinical research program with CellCept & Zenapax which aims to optimize patient outcomes in the long term.

SANOFI-SYNTHELABO, INC.

BOOTH #606

90 Park Avenue

New York, NY 10016

Phone: 212-551-4245

Fax: 212-551-4913

Contact: Christine Hadjis

Sanofi-Synthelabo welcomes you to Vancouver! Please visit our exhibit to talk with our staff about Primacor® (milrinone lactate injection). For more information on Primacor®, please visit our website: [www.Primacor.com](http://www.Primacor.com).

SANGSTAT

BOOTH #602

6300 Dumbarton Circle

Freemont, CA 94555

Phone: 510-789-4300

Fax: 510-789-4202

Contact: Isabelle Mercier, Product Sales Manager

SangStat is a global biotechnology company building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. Since 1988, SangStat has been dedicated to

improving the outcome of organ and bone marrow transplantation through the development and marketing of products to address all phases of transplantation in the worldwide market. SangStat Marketed Products include Gengraf™ (Co-Promotion with Abbott Laboratories Inc.), Thymoglobulin®, Thymoglobuline®, Lymphoglobuline®, Celsior®.

SCANLAN INTERNATIONAL, INC.

BOOTH #210

One Scanlan Plaza

Saint Paul, MN 55107

Phone: 651-298-0997

Fax: 651-298-0018

Contact: Jennifer Cobian, Senior Sales Administration Manager

THORATEC CORPORATION

BOOTH #403

6035 Stoneridge Drive

Pleasanton, CA 94588

Phone: 925-847-8600

Fax: 925-847-8574

Contact: Julie Tracy

Thoratec Laboratories has recently united with Thermo Cardiosystems, Inc. to become Thoratec Corporation. The combination of two dedicated circulatory support companies provides surgeons and cardiologists with the broadest range of complementary cardiac assist product offerings for the treatment of congestive heart failure. The HeartMate® VAD System is ideally suited for short to mid-term right, left or bi-ventricular supporting patients of almost any size. Additionally, Thoratec also manufactures a line of coronary artery bypass grafts and vascular access grafts.

ISHLT REGISTRY

BOOTH #509

1100 Boulders Pkwy, Suite 500

Richmond, BA 23225

Phone: 804-330-8500

Fax: 804-327-1449

Contact: Berkeley Keck

The ISHLT Transplant/Mechanical Circulatory Assist Device Database collects worldwide transplant and assist device data. Data are utilized for scientific study to increase the body of knowledge regarding thoracic transplantation and cardiac device management. This year's exhibit will feature online availability of center-specific analysis for review by ISHLT members who represent the center submitting the data. In addition, ISHLT members can view preliminary screens for the new device database and receive information on how to provide data to the transplant and device databases.

VITROLIFE

BOOTH #108

Molndalsvagen 30

412 63 Goteborg

Sweden

Phone: 46-31-721-80-60

Fax: 46-31-721-80-95

Contact: Beatrice Mikaelsson

Vitrolife develops specialized media and devices facilitating a physiological preservation of organs, tissues and cells. The products of Vitrolife Transplantation Systems divisions are clinically proven solutions supporting Thoracic and Cardio-vascular surgery. Vitrolife's Perfadex products are optimized for preservation of lung grafts for transplantation and vascular grafts for coronary by-pass surgery.

WORLD HEART CORPORATION

BOOTH #109

1 Laser Street

Ottawa, Ontario

Canada K2E 7V1  
Phone: 613-226-4278  
Fax: 613-723-8522  
Contract: Jennifer Poulsen

World Heart Corporation is a global medical device company currently focused on the development and commercialization of pulsatile ventricular assist devices (VAD). Its Novacor® Left Ventricular Assist System is already well established in the marketplace and its next generation technology, HeartSaverVAD™, is being developed as a fully implantable heart system for patients with end-stage heart disease. World Heart Corporation has offices in Canada and the United States.

### **Scientific Program Committee**

David O. Taylor, MD, 2001 Program Chair, Salt Lake City, UT  
Anne Keogh, MD, ISHLT President, Sydney, Australia  
James B. Young, MD, President-Elect, Cleveland OH  
Jon Kobashigawa, MD, 2000 Program Chair, Los Angeles CA  
Robert C. Robbins, MD, 2002 Program Chair, Stanford CA  
James K. Kirklin, MD, JHLT Editor, Birmingham AL  
Nicholas Banner, MD, Harefield, Middlesex, United Kingdom  
Duane Davis, MD, Durham, NC  
Michael C. Fishbein, MD, Los Angeles, CA  
James F. George, PhD, Birmingham, AL  
Allan R. Glanville, MD, Sydney, Australia  
Valluvan Jeevanandam, MD, Chicago IL  
Joren C. Madsen, MD, D.Phil., Boston, MA  
Keith McNeil, FRACP, Cambridge, United Kingdom  
Bruno Meiser, MD, Munich, Germany  
Linda Ohler, RN, MSN, Bethesda MD  
Hermann Reichenspurner, MD, PhD, Munich, Germany  
Bruce R. Rosengard, MD, Philadelphia PA  
Heather J. Ross, MD, Toronto, Canada  
Ralph A. Schmid, MD, Berne, Switzerland  
Robert E. Shaddy, MD, Salt Lake City, UT  
Henry Tazelaar, MD, Rochester, MN  
Lori J. West, MD, PhD, Toronto, Canada  
George Wieselthaler, MD, Vienna, Austria

### **Abstract Reviewers**

David H. Adams, MD, Boston, MA  
Juan Alejos, MD, Los Angeles, CA  
James B. Atkinson, MD, PhD, Nashville, TN  
Mark L. Barr, MD, Los Angeles, CA  
William A. Baumgartner, MD, Baltimore, MD  
Peter Bergin, MBBS, FRACP, Victoria, Australia  
Annette Boehler, MD, Zurich, Switzerland  
Steve F. Bolling, MD, Ann Arbor, MI  
R.M. Bolman, III, MD, Minneapolis, MN  
Nancy D. Bridges, MD, Philadelphia, PA  
Margaret Burke, MB, MRCPATH, Harefield, United Kingdom  
Noreen Caine, BA, Cambridge, United Kingdom  
John V. Conte, MD, Baltimore, MD  
David KC Cooper, MD, PhD, FRCS, Boston, MA  
Paul A. Corris, MD, FRCP, Newcastle Upon Tyne, United Kingdom  
Sandra A. Cupples, DNSc, RN, Potomac, MD  
John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom  
Mary Amanda Dew, PhD, Pittsburgh, PA  
Robert D. Dowling, MD, Louisville, KY  
Ramona L. Doyle, MD, Stanford, CA  
John J. Dunning, FRCS, Cambridge, United Kingdom  
Niloo M. Edwards, MD, New York, NY  
Howard J. Eisen, MD, Philadelphia, PA  
Aly El-Banayosy, MD, Bad Oeynhausen, Germany  
Daniel P. Fishbein, MD, Seattle, WA  
Peter E. Fisher, MD, New York, NY  
Maureen P. Flattery, RN, MSN, Richmond, VA  
Satoshi Furukawa, MD, Philadelphia, PA  
Alan Gass, MD, New York, NY  
Martin J. Goddard, FRCSJ, Cambridge, United Kingdom  
Bartley P. Griffith, MD, Pittsburgh, PA  
Edoardo Gronda, MD, Milan, Italy  
Ari LJ Harjula, MD, Helsinki, Finland

Alain Heroux, MD, Chicago, IL  
Marshall I. Hertz, MD, Minneapolis, MN  
Roland Hetzer, MD, PhD, Berlin, Germany  
Robert SD Higgins, MD, Richmond, VA  
Gregory M. Hirsch, MD, Halifax, Canada  
Francis M. Hoffman, RN, MSN, Minneapolis, MN  
Daphne T. Hsu, MD, New York, NY  
Manfred Hummel, MD, PhD, Berlin, Germany  
Debra L. Isaac, MD, Calgary, Canada  
Annemarie Kaan, RN, Sydney, Australia  
Shaf Keshavjee, MD, Msc, FRCSC, Toronto, Canada  
Wolfgang F. Konertz, Jr., MD, Berlin, Germany  
Robert L. Kormos, MD, Pittsburgh, PA  
Christine Lawless, MD, FACC, Maywood, IL  
James W. Long, MD, PhD, Salt Lake City, UT  
Charles C. Marboe, MD, New York, NY  
Hikaru Matsuda, MD, Osaka, Japan  
Patrick M. McCarthy, MD, Cleveland, OH  
Christopher McGregor, MD, FRCS, Rochester, MN  
Bruce McManus, MD, PhD, Vancouver, Canada  
Mandeep R. Mehra, MD, New Orleans, LA  
Robert Michler, MD, Columbus, OH  
Leslie W. Miller, MD, Minneapolis, MN  
Yasuo Morishita, MD, Gunma, Japan  
Mehmet C. Oz, MD, New York, NY  
Wayne D. Paris, MSW, Oklahoma City, OK  
Francesco Parisi, MD, Rome, Italy  
Richard N. Pierson, III, MD, Nashville, TN  
Jochum Prop, MD, PhD, Groningen, The Netherlands  
Barry K. Rayburn, MD, Birmingham, AL  
Dale G. Renlund, MD, Salt Lake City, UT  
Mauro Rinaldi, MD, Pavia, Italy  
Marlene Rose, PhD, Harefield, United Kingdom  
Stephan Schueler, MD, Dresden, Germany  
Julie A. Shinn, RN, MA, Stanford, CA  
Nicholas G. Smedira, MD, Cleveland, OH  
Gregory I. Snell, FRACP, MBBS, Melbourne , Australia  
Benjamin C. Sun, MD, Hershey, PA  
Thoralf M. Sundt, MD, St. Louis, MO  
George Tellides, MD, New Haven, CT  
Guillermo Torre, MD, PhD, Houston, TX  
Vincent G. Valentine, MD, New Orleans, LA  
Dirk Van Raemdonck, MD, PhD, Leuven, Belgium  
Wolfgang Von Scheidt, MD, Munich, Germany  
Ludwig von Segesser, MD, Lausanne, Switzerland  
Thomas K. Waddell, MD, PhD, Toronto, Canada  
Florian Wagner, MD, Dresden, Germany  
Steven A. Webber, MB, ChB, Pittsburgh, PA  
Willem Weimar, MD, Rotterdam, The Netherlands  
Robert G. Weintraub, MBBS, FRACP, Parkville, Australia  
Thomas D. Wekerle, MD, Vienna, Austria  
Gayle L. Winters, MD, Boston, MA  
Adriana Zeevi, PhD, Pittsburgh, PA  
Mark Zucker, MD, JD, Newark, NJ